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Toxoplasma gondii is an obligate intracellular apicomplexan parasite that causes life-
threatening disease in neonates and in immunocompromised people. Successful replication of 
Toxoplasma requires substantial membrane biogenesis, which must be satisfied irrespective of 
the host-cell milieu. Like in other eukaryotes, the two most abundant phospholipids in the T. 
gondii membrane are phosphatidylcholine (PtdCho) and phosphatidylethanolamine (PtdEtn). 
Bioinformatics and precursor labeling analyses confirm their synthesis via the CDP-choline 
and CDP-ethanolamine pathway, respectively. This work shows that the 3-step CDP-choline 
pathway, involving the activities of TgCK, TgCCT and TgCPT, localizes to the cytosol, 
nucleus and ER membrane, respectively. The initial reaction is catalyzed by a dual-specificity 
choline kinase (TgCK, ~70-kDa), capable of phosphorylating choline as well as ethanolamine. 
The purified full-length TgCK displayed a low affinity for choline (Km ~0.77 mM). TgCK 
harbors a unique N-terminal hydrophobic peptide that is required for the formation of enzyme 
oligomers in the parasite cytosol but not for activity. The displacement of the TgCK promoter 
in a conditional mutant of T. gondii (∆tgcki) attenuated the enzyme expression by ~80%. 
Unexpectedly, the ∆tgcki mutant was not impaired in intracellular growth, and exhibited a 
normal PtdCho biogenesis. To recompense for the loss of full-length TgCK, the mutant 
appears to make use of an alternative promoter and/or start codon, resulting in the expression 
of a shorter but active TgCK isoform identified by the anti-TgCK antiserum, which correlated 
with its persistent choline kinase activity. Accordingly, the ∆tgcki showed an expected 
incorporation of choline into PtdCho, and susceptibility to dimethylethanolamine (a choline 
analog). Interestingly, the conditional mutant displayed a regular growth in off state despite a 
25% decline in PtdCho content, which suggests a compositional flexibility in T. gondii 
membranes and insignificant salvage of host-derived PtdCho. The two-step conditional 
mutagenesis of TgCCT, which caused a reduced growth rate to about 50%, further 
substantiated this finding. The enzymatic activity of TgCCT and its role in PtdCho synthesis 
remain to be proven, however.  
Taken together, the results demonstrate that the CDP-route is likely essential in T. gondii. The 
competitive inhibition of choline kinase to block the parasite replication appears a potential 
therapeutic application.The work also reveals a remarkably adaptable membrane biogenesis in 





Der obligat intrazelluläre Parasit Toxoplasma gondii ist der Erreger der Toxoplasmose, und 
dient zugleich als wichtiger Modellorganismus für weitere Human- und Tierpathogene, wie 
z.B. Plasmodium oder Eimeria. Die Vermehrung von T. gondii erfordert eine effiziente 
Biosynthese von Phospholipiden für die Herstellung neuer Membranen, was durch die de 
novo Synthese durch den Parasiten, und/oder den Import von Lipiden aus der umgebenden 
Wirtszelle gewährleistet werden kann. Während der Parasit zahlreiche Möglichkeiten für 
Synthese oder Import von PtdEtn und PtdSer verwendet, scheint die Biosynthese des 
abundantesten Membranlipids PtdCho auschließlich über den CDP-Cholin Weg zu erfolgen. 
Dieser erstreckt sich in T. gondii über 3 zelluläre Kompartimente, mit einer cytosolischen 
Cholin-Kinase (TgCK), einer im Zellkern lokalisierenden Cholin-Cytidylyltransferase 
(TgCCT) und einer Cholin-Phosphotransferase (TgCPT) im ER. Anders als die substrat-
spezifische Ethanolamin-Kinase (TgEK), kann TgCK neben Cholin außerdem Ethanolamin 
phosphorylieren. TgCK zeigt eine geringe Affinität zu Cholin (Km ~0.77 mM), während eine 
verkürzte TgCK (TgCKS), welcher eine als Signalpeptid vorhergesagte N-terminale Sequenz 
(20 Aminosäuren) fehlt, eine etwa 3-fach höhere Aktivität aufweist (Km ~0.26 mM). Während 
jedoch die Wildtyp-TgCK cytosolische Cluster in Toxoplasma bildet, zeigt die verkürzte 
TgCK eine gleichmäßigere cytosolische Lokalisierung. Wir schlussfolgern daraus, dass der 
hydrophobe N-Terminus nicht notwendig ist für eine funktionale TgCK, sondern eine 
strukturelle Funktion bei der Protein-Lokalisierung hat. Eine konitionelle Mutante, in welcher 
der TgCK Promoter gegen den Tetracyclin-regulierbaren Promoter pTetO7Sag4 ausgetauscht 
wurde (∆tgcki), zeigt erstaunlicherweise normales Wachstum und PtdCho Biosynthese. Die 
TgCK Aktivität und die daraus resultierende PtdCho Synthese sind nur zu ~30% regulierbar. 
Unsere Ergebnisse deuten auf die Verwendung eines alternativen Startcodons bzw. Promoters 
hin, welcher zur Expression einer verkürzten (~53-kDa) aber vermutlich aktiven Cholin 
Kinase führt, wodurch der Verlust der TgCK (~70-kDa) kompensiert wird. 
Der konditionelle Knockout von TgCCT, dem regulatorischen Enzym des CDP-Cholin Wegs, 
hatte einen 50%igen Wachstumsdefekt zur Folge.  
Diese Studie zeigt eine erstaunliche Flexibilität des Parasiten bezüglich seiner 
Membranzusammensetzung, und bestätigt zugleich die Annahme, dass PtdCho nicht von der 
Wirtszelle importiert werden kann. Diese Anpassungsfähigkeit stellt einen möglichen Faktor 





APR Apical polar ring 
ATc Anhydro-tetracycline 
ATP Adenosine triphosphate 
CAT Chloramphenicol acetyltransferase 
CCT Choline cytidylyltransferase 
cDNA  complementary deoxyribonucleic acid 
CHCl3 Chloroform 
CK Choline kinase 
CPT CDP-choline phosphotransferase 
DAPI 4’,6-diamidino-2-phenylindole 
DHFR-TS Dihydrofolate reductase thymidylate synthase 
DME Dimethylethanolamine 
DMEM Dulbeccos’s modified Eagle medium 
DNA Deoxyribonucleic acid 
EDTA Ethylendiamine tetraacetate 
EK Ethanolamine kinase 
ER Endoplasmic reticulum 
EtOH Ethanol 
FAS I/II Fatty acid synthase type I/II 
FCS Fetal calf serum 
FUdR 5-Fluoro-2’-deoxyuridine 
HFF Human foreskin fibroblast 
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H.O.S.T. Host Organelle Sequestering Tubulo-Structures 
HXGPRT Hypoxanthine-xanthine-guanine phosphoribosyl transferase 
IEM Immunoelectron microscopy 
IFA Indirect immunofluorescence assay 
IMC Inner membrane complex 
IPTG Isopropyl-ß-D-1-thiogalactopyranoside 
IVN Intravacuolar network 
LDL Low-density lipoprotein 
LiAc Lithium acetate 
MeOH (CH3OH) Methanol 
MTOC Microtubule organizing center 
NADH Nicotinamide adenine dinucleotide 
NLS Nuclear localization signal 
NBD 7-nitrobenz-2-oxa-1,3-diazol-4-yl 
ORF Open reading frame 
PBS Phosphate buffered saline 
PCR Polymerase chain reaction 
PEG Polyethylene glycol 
PEMT Phosphatidylethanolamine methyltransferase 
PfPMT phosphoethanolamine methyltransferase (Plasmodium falciparum) 





PV Parasitophorous vacuole 
PVM PV membrane 
RNA Ribonucleic acid 
SDS Sodium dodecyl sulfate 
TaTi Trans-activator trap identified 
TLC Thin layer chromatography 
UPRT Uracil phosphoribosyl transferase 
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1.1  Introduction to Toxoplasma gondii 
1.1.1 Toxoplasma gondii: life cycle and disease 
 Toxoplasma belongs to the phylum Apicomplexa, a diverse group of obligate intracellular 
parasites, many of which inflict devastating diseases in human and animals, such as malaria, 
toxoplasmosis and coccidiosis (1). Unlike other intracellular parasites, which usually have a 
narrow host range, T. gondii has an exceptional ability to replicate in most vertebrate cells. 
The wide host range of T. gondii makes toxoplasmosis one of the most common parasitic 
infections of humans and animals. Up to one third of the population worldwide is estimated to 
harbor the parasite. The seroprevalence, however, varies strongly between countries, with 
about 20-80% in Europe and 23% in the USA (2,3). Infection with T. gondii is usually 
asymptomatic but it can cause life-threatening encephalitis and systemic infections in 
neonates and in immunocompromised individuals.  
The natural life cycle of Toxoplasma involves a sexual phase in feline species, and an asexual 
phase, which can occur in virtually all warm-blooded hosts (Fig. 1). The intermediate host can 
acquire the parasite by ingestion of the infected feed or undercooked meat. Upon ingestion, 
the parasite immediately invades host cells to commence its asexual and lytic cycle. The 
invasive tachyzoite stage is capable of converting into the dormant bradyzoite stage, 
preferentially in the central nervous system or muscle tissue, which can persist as tissue cysts 
for life. These cysts can be reactivated to become actively replicating tachyzoites upon decay 
of the host immune response. Tachyzoites have a doubling time between 8-10 hrs, and cause a 
tissue lysis by sequential events of invasion, replication, egression and re-invasion of 
neighboring host cells. The ingestion of infected mice carrying tissue cysts by cats results in 
parasite invasion into the gut epithelium cells of the feline host and subsequent onset of sexual 
stages (Fig. 1). The merozoites in the intestine differentiate into macro- and microgametes, 
which fuse to form the oocyst. These oocysts are shed into the environment and harbor 2 
sporocysts each enclosing 4 sporozoites. Accidental ingestion of the sporulated oocysts 




Fig. 1: Life cycle of Toxoplasma gondii.  The life cycle involves a sexual phase, which is resticted to 
feline species only. The asexual phase can occur in most warm-blooded animals including human. 
Oocysts shed in the environment can be ingested by an intermediate host, where sporozoites are 
released and develop into the replicative tachyzoite stage. Tachyzoites undergo a lytic life cyle (acute 
infection) and can transform into bradyzoites (chronic infection) in response to host immune system 
(1). 
 
1.1.2 Subcellular organelles and cell division 
Members of the phylum apicomplexa are higly polarized cells and share an apical complex 
harboring the conoid and a set of unique secretory organelles, micronemes, rhoptries and 
dense granules. These organelles play a crucial role in the active invasion and subsequent 
modification of the host environment (4). Toxoplasma displays a typical eukaryotic 
morphology comprising of a nucleus, perinuclear endoplasmic reticulum, an elongated lunate-
shaped mitochondrion, and a single Golgi stack. The apicoplast, a plastid of cyanobacterial 
origin acquired by secondary endosymbiosis and therefore enclosed by 4 membranes, is also 
present in most apicomplexans except in Cryptosporidium (5). The structural integrity of the 
parasite is ensured by a pellicle, consisting of the subpellicular microtubules and the inner 
membrane complex (IMC), a system of flattened membrane cisternae underlying the plasma 
membrane (6). The microtubules emerge from an apical microtubule organizing center 
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(MTOC) located at the basal end of the conoid (7). T. gondii possesses a haploid genome 
throughout its asexual replication. Two extrachromosomal genomes are present in the 
apicoplast and mitochondrion of T. gondii (8).  
 
 
Fig. 2: Schematic depiction of structure and cell division of T. gondii. (A) conoid (black lines), 
inner membrane complex (light green lines), rhoptries (turquoise), micronemes (lavender), dense 
granules (blue), apicoplast (pink), mitochondrion (red), Golgi (gold), nucleus (grey), endoplasmic 
reticulum (yellow); (B) developing daughter IMC scaffolds (dark green). Adapted from Nishi et al. (9) 
 
The cell division in tachyzoites proceeds via endodyogeny, in which two progenies are 
formed within an intact mother cell (Fig. 2). First indication of cell division is the duplication 
of centrioles, which definines a mitotic spindle (10). Centriole duplication occurs with the 
concurrent elongation and fission of the Golgi (11). The DNA replication is initiated and the 
IMC scaffold emerges from the apical polar ring (APR)-MTOC (10). The extension of the 
microtubule network from the APR towards the posterior end of the budding parasite causes 
the partitioning of the mother nucleus and cytoplasm. The division of maternal mitochondrion 
and ER occurs late during the division, which are distributed equally in the daughter cells. 
Unlike other organelles, rhoptries and micronemes are formed de novo in each daughter cell 
presumably by vesicular budding from the Golgi stack. The mitochondrion and apicoplast 
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harbor their own genomes, which undergo division before (apicoplast) or immediately after 
(mitochondrion) the karyokinesis (9,12). The newly formed daughter parasites acquire their 
plasma membrane from the mother cell, leaving behind only a small residual body.  
 
1.2  Genetic manipulation of T. gondii 
1.2.1 Selection markers 
Over the last two decades a wide spectrum of methods to manipulate the haploid genome of 
Toxoplasma tachyzoites has been established. The two crucial achievements were the 
establishment of transfection via electroporation of tachyzoites (13) and the completion of the 
genome sequencing (www.ToxoDB.org). Toxoplasma serves as an excellent model organism 
to study the biology of apicomplexan parasites, due to relative ease of genetic manipulation 
and well established culture of the infectious tachyzoite stage. (14). 
The stable transfection makes use of selection markers to generate transgenic parasites. An 
observation that wild-type strains of T. gondii are sensitive to inhibitors of prokaryotic 
translation, such as chloramphenicol, and introduction of the chloramphenicol 
acetyltransferase (CAT) gene renders the parasite resistant to drug, led to the development of 
CAT as a positive selection marker (15). Based on pyrimethamine-resistance in Plasmodium, 
introduction of point mutations in the TgDHFR-TS protein provided a positive selection 
system for transgenic work (16). Significantly higher frequency of stable transformation was 
achieved by exploitation of the parasite’s dihydrofolate reductase-thymidylate synthase 
(DHFR-TS). A yet another approach exploits the parasite purine salvage pathway. The 
hypoxanthine-xanthine-guanine phosphoribosyl transferase (HXGPRT) can be used as a 
positive as well as a negative selection marker, because its absence confers resistance to 6-
thioxanthine (6-TX), whereas the ectopic expression of HXGPRT in null background can 
rescue the parasite from mycophenolic acid in the presence of exogenous xanthine (17). 
Uracil phosphoribosyl transferase (UPRT) is largely dispensable for T. gondii tachyzoite 
survival and its replacement by foreign DNA renders the tachyzoites resistant to 5-fluoro-
deoxyuridine (FUDR) (18).  This phenomenon can be exploited to target genes of interest to 
the UPRT locus by negative selection.  
Other selection methods include the Streptoalloteichos or Tn5 ble gene product, which can 
protect from the DNA-damaging activity of phleomycin. The selection must be applied on 
extracellular tachyzoites, which makes it inconvenient and thus a less common marker.  
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1.2.2 Conditional versus direct gene deletion 
The haploid genome of T. gondii tachyzoites makes it easier to study the gene function by 
direct deletion mediated by double homologous recombination. The constructs harboring the 
5’- and 3’-UTRs of the gene of interest flanking a resistance cassette allow replacement or 
disruption of the open reading frames. The resultant clonal transgenic parasite lines can be 
phenotyped. The deletion of essential genes, however, is lethal to the parasite due to its 
haploid nature. To this end, conditional manipulation of T. gondii has been established, which 
permits regulation of gene expression in response to specific ligands. The tetracycline 
transactivator-based “tet-off” method controls the gene expression at the transcriptional level 
(19,20). Fusion of a Toxoplasma transactivation domain with the E. coli Tet-repressor (TetR) 
in the TATi (trans-activator trap identified) tachyzoites allows a controlled gene expression 
through a minimal parasite promoter fused with “tetO” (Tet operator) elements. Transcription 
is reversibly blocked by anhydro-tetracycline (ATc), which displaces the transactivator from 
the operator. Conditional mutagenesis can be performed by direct replacement of the native 
gene promoter by the tetracycline regulatable promoter. Alternatively, a regulatable cassette 
can be introduced into the parasite genome, and then the native locus can be ablated by double 
crossover.  
The essential genes can also be examined by modulation of the protein stability. Fusion of a 
destabilization domain (ddFKBP) with the target protein leads to its proteasomal degradation, 
unless the domain is masked by a ligand known as Shield-1 (21,22). This system allows a fast 
and efficient control of proteins fused with ddFKBP-domain.  
 
1.2.3 Recombination versus random integration 
The ablation of gene function by direct deletion in Toxoplasma gondii has proven difficult due 
to a lower frequency of crossover, which could only be counteracted by constructs with longer 
(>2kb) crossover sequences. This was recently attributed to the presence of non-homologous 
end-joining (NHEJ) pathways in T. gondii, mediated by a protein complex, which facilitate 
the direct repair of double strand breaks in DNA (23,24). A heterodimer of Ku70 and Ku80 
binds to the broken and free DNA ends, and subsequently recruits a DNA-dependent protein 
kinase and the DNA-ligase-IV-XRCC4 complex. This results in ligation of the DNA breaks 
(25). The attempts to delete Ku70 and DNA-ligase-IV genes have failed which appear to be 
essential in T. gondii. The type I and type II (23,24,26) strain lacking the Ku80 gene have 
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been generated, which show a much improved efficiency of homologous recombination. 
These strains are now widely used for genetic manipulation to study the biology of tachyzoite 
and bradyzoite stages, respectively. 
 
1.3  Membrane biogenesis in eukaryotic cells 
1.3.1 Introduction to neutral and polar lipids 
Lipids are defined as hydrophobic ingredients of biological membranes, which are readily 
soluble in the organic solvents. There is a great diversity of lipid species differing in their 
structure and function, which can be broadly classified as triacylglycerols, phospholipids, 
sphingolipids and neutral lipids (Fig. 3). The main constituents of biological membranes are 
phospholipids and neutral lipids the former of which are amphipathic molecules with two 
fatty acid chains at the sn-1 and sn-2 positions of a glycerol backbone and a phosphate or 
polar head group at sn-3 position.  The polar head group is usually choline, ethanolamine, 
serine or inositol. In a hydrophilic milieu, e.g. the cell cytosol, phospholipids spontaneously 
self-assemble to form a bilayer, in which the acyl chains face the hydrophobic interior and the 
hydrophilic phosphate and head groups interact with the aqueous milieu. The primary role of 
lipids is the formation of lipid bilayers surrounding the organelles, in addition to their 
functions as energy store or as signaling molecules. 
The second most abundant class of membrane lipids is cholesterol, which differs significantly 
from phospholipids. Cholesterol is a member of the steroid lipids and is composed of 20 
carbon atoms arranged as four hydrocarbon rings, 3 cyclohexanes and 1 cyclopentane. A 
hydroxyl group is attached to the C3 position, and the C17 in the cyclopentane ring harbors an 
alkyl side chain. Its amphipathic character allows interaction with the polar headgroups of 
neighboring phospholipids through the hydroxyl group, while the hydrophobic ring and alkyl 
chain are embedded in the core of the bilayer. Cholesterol provides rigidity to the membrane 
and regulates its permeability for small molecules.  
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Fig. 3: Major classes of lipids present in most eukaryotic membranes. Lipids are broadly classified 
into phospholipids, glycolipids and sterols. Phospholipids are composed of a glycerol backbone, which 
carries two fatty acid chains and a phosphate or polar head group (choline, etc.). Sphingolipids consist 
of a sphingosine moiety, which harbors an acyl chain and a sugar residue or a phosphorylated head 
group. Sterols are generally composed of four carbon rings, an alkyl chain, and a hydroxyl group.  
 
1.3.2 De novo synthesis of lipids in mammalian cells 
Lipids synthesis in mammalian cells is highly interconnected and consists of two independent 
pathways for the formation of each phospholipid. It begins with cytosolic and/or nuclear 
enzymes; however, the eventual sites of lipid biosynthesis are the endoplasmic reticulum and 
the mitochondria. PtdEtn, PtdCho and PtdSer are synthesized from their respective precursors 
ethanolamine, choline and serine, and further interconverted into eachother (Fig. 4).   
Choline is metabolized into PtdCho via the CDP-choline pathway (27,28). Choline, an 
essential nutrient, is phosphorylated to phosphocholine by a choline kinase (CK) in the 
cytosol. The phosphocholine cytidylyltransferase (CCT) then catalyzes the fusion of 
phosphocholine with CTP to produce CDP-choline. The product is finally converted into 
PtdCho via transfer of the phosphocholine moiety to diacylglycerol (DAG) catalyzed by 
CDP-choline phosphotransferase (CPT). PtdCho can also be made from PtdEtn via a three-
step methylation reaction catalyzed by a PtdEtn methyltransferase (PEMT). The CDP-
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ethanolamine pathway is analogous to the above pathway and involves activity of EK, ECT 
and EPT to generate PtdEtn from ethanolamine (27). Alternatively, PtdEtn can be made from 
PtdSer using a PtdSer decarboxylase, which is localized in the mitochondria. PtdSer in 
mammalian cells is produced by a PtdSer synthase, exchanging serine for the head group from 
PtdCho (PSS-1) or PtdEtn (PSS-2) (27). The DAG is mainly derived from phosphatidic acid 
(PtdOH) by the action of a phosphatase. 
 
Fig. 4: De novo synthesis of phospholipids in mammalian cells. CK, choline kinase; CPT, CDP-
choline phosphotransferase; DAG, diacylglycerol; EK, ethanolamine kinase; EPT, CDP-ethanolamine 
phosphotransferase; PCT, phosphocholine cytidylyltransferase; PET, phospho-ethanolamine 
cytidylyltransferase; PEMT, phosphatidylethanolamine methyltransferase; PSD, phosphatidylserine 
decarboxylase; PSS, phosphatidylserine synthase; PtdCho, phosphatidylcholine; PtdEtn, 
phosphatidylethanolamine; PtdOH, phosphatidic acid; PtdSer, phosphatidylserine 
 
Mammalian cells are also capable of synthesizing cholesterol via the mevalonate pathway, a 
multi-step pathway named after a key metabolic intermediate of the rate-limiting reaction 
catalyzed by hydroxymethyl-glutaryl (HMG)-CoA reductase (29). The cholesterol 
biosynthesis is tissue-specific and mainly occurs in the liver, from where it is exported via 
low-density lipoproteins (LDL) to other tissues in esterified form. The LDL can be 
internalized by other cells using LDL-receptor mediated endocytosis (30). The cholesterol is 
utilized for membrane biogenesis, in the formation of vitamins and steroid hormones, and for 
cellular signalling.  
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1.3.3 Intracellular trafficking of lipids in eukaryotic cells 
Not only do the subcellular membranes vary in their lipid composition, the two leaflets of the 
bilayer are selectively enriched in individual lipids. Moreover, the final reactions of lipid 
synthesis occur in the ER- or mitochondrial membranes from where lipids must be distributed 
to other cellular organelles. To facilitate the process, lipids can shuttle between the organelles 
via carrier vesicles (31).  
The lipid trafficking, however, is partially insensitive to drugs blocking vesicular transport, 
which indicates the presence of alternative non-vesicular routes for lipid movement (32). 
Tight apposition of two membranes can provide contact zones for lipid exchange, such as the 
mitochondria-associated membranes (MAM), the contact sites between the ER and 
mitochondria (33). Finally, lipid trafficking and movement can also occur via specific carrier 
proteins. This includes lipoproteins for cholesterol, the ceramide transport protein (CERT), 
and the ATPases between the membrane leaflets. The plasma membrane shows an asymmetric 
distribution of phospholipids, in which PtdCho and sphingolipids are enriched in the outer 
exoplasmic leaflet, and PtdSer and PtdEtn on the inner cytoplasmic face of the membrane 
(34). This lipid asymmetry is mainly due to two types of flippases, the ABC (ATP-binding 
cassette)-transporter catalyzing the outward-directed movement (“flop”) of lipids, and the P4-
type ATPases, which translocate lipids to the inner leaflet (“flip”) (35). 
  
1.3.4 Phospholipid synthesis in Toxoplasma 
Successful replication of T. gondii requires substantial biogenesis of the parasite organelle and 
plasma membranes. Further, the parasite growth must be accompanied by enlargement of the 
enclosing parasitophorous vacuolar membrane (PVM). The T. gondii membrane consists 
primarily of phospholipids and neutral lipids, and minor plant-like lipids (36,37). Similar to 
other eukaryotic cells, PtdCho is the most abundant lipid in T. gondii. The lipid analyses of 
human host cell (HFF) and the tachyzoites have revealed a higher content of PtdCho in the 
parasite. PtdCho accounts for ~75% of total phospholipids in T. gondii, which is followed by 
PtdEtn (10%), PtdIns (7.5%), PtdSer (6%) and PtdOH (1.5%) (38). Moreover, the parasite 
phospholipids preferentially contain shorter-chain and more saturated fatty acid (37). The 
precursor labeling assays have shown that Toxoplasma can utilize choline, ethanolamine and 
serine into PtdCho, PtdEtn and PtdSer, respectively (38,39). This has been substantiated by 
enzyme assays and bioinformatic analyses. Unlike other eukaryotes, however, Toxoplasma 
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does not possess gene annotations or activity for PEMT, and appears incompetent in making 
PtdCho from PtdEtn (38). There is also no evidence for a plant-type phospho-ethanolamine 
methyltransferase in T. gondii, which has been identified exclusively in P. falciparum (40). 
These findings suggest a strict dependence of T. gondii on its CDP-choline pathway (i.e. 
choline auxotrophy) to sustain its PtdCho biogenesis. 
Shortly after invasion dense granule proteins are released into the PV lumen lumen, of which 
a complex of Gra2, Gra4 and Gra6 proteins is implicated in biogenesis of the intravacuolar 
network (IVN), which originates from multi-lamellar vesicles, secreted at the posterior end of 
the parasite (41,42). The IVN is thought to provide a large surface area and potentially serves 
as a conduit for nutritional exchange between T. gondii and its host. The selective labeling of 
host or parasite lipids indicated the flow and assimilation of host-derived lipids across the 
PVM to the IVN, which might contribute to enlargement of the PVM (43). However, whether 
the PVM expansion is accomplished by translocation of parasite-derived lipids or via 
recruitment of host lipids is not fully understood.  
The intracellular parasite extensively modifies its host cell to gain access to a variety of 
nutritional compounds, which are either imported via specific transporters, or can freely 
diffuse through the 1.3 kDa pores in the PVM (44). The PVM is juxtaposed with host 
endoplasmic reticulum and mitochondria (45), which are the major sites of lipid synthesis in 
the mammalian host. These organelles can therefore potentially offer a source for host-derived 
lipid for the parasite.  
 
1.4 Objective of this study 
Toxoplasma gondii as an obligate intracellular parasite requires biogenesis of subcellular 
membranes to ensure a faithful replication. Whether the parasite fulfills the demand of 
phospholipids by de novo synthesis and/or salvaging of host-derived lipids is not understood. 
Axenic T. gondii can incorporate free choline into its most abundant lipid PtdCho; however, at 
much lower rate (~9%) than required for the cell doubling (38). The aim of this work was to 
investigate the relative dependence of T. gondii on de novo CDP-choline pathway and host-





2 Materials and Methods 
 
2.1  Materials 
2.1.1  Biological resources 
Cell Line Source 
Human Foreskin Fibroblasts (HFF) Carsten Lüder, University of Göttingen, Germany 
T. gondii tachyzoites (RH hxgprt
-
) Dominique Soldati-Favre, University of Geneva, 
Switzerland 
T. gondii tachyzoites (TaTi-∆ku80 strain)  Boris Striepen, University of  Georgia, USA 
T. gondii tachyzoites (∆ku80 strain) Vern Carruthers, University of Michigan, Ann 
Arbor, USA 
COS-7  Isabelle Coppens, Johns Hopkins University, 
Baltimore, USA 
E.coli (XL-1blue, Rosetta)  Stratagene, Germany 
Saccharomyces cerevisiae (KS106)   
(MATα eki1∆::TRP1 cki1∆::HIS3 leu2-3,112 
ura3-1 trp1-1 his3-11,15 ade2-1 can1-100) 
George Carman, Rutgers University, New 
Brunswick, USA 
Saccharomyces cerevisiae Y04832 
(MAT a; his3∆1; leu2∆0; met15∆0; ura3∆0; 
YGR202c::kanMX4) 
Euroscarf, Frankfurt 
Saccharomyces cerevisiae Y04637 
(MAT a; his3∆1; leu2∆0; met15∆0; ura3∆0; 
YGR007w::kanMX4) 
Euroscarf, Frankfurt 
Saccharomyces cerevisiae HJ000 
MATa his3-∆1 leu2-3,112 ura3-52 trp1-289 
cpt1::LEU2 ept1-∆1::URA3 




2.1.2 Chemical reagents 
Product Manufacturer 
Adenosinetriphosphate (ATP) Sigma, Germany 
Albumin Fraction V  Applichem, Germany  
Aluminium hydroxide Fluid Gel Reheis, Ireland 
Ammonium acetate   Roth, Germany 
Ammonium molybdate Applichem, Germany 
Ammonium persulfate Sigma, Germany  
Ammonium Reineckate salt Sigma, Germany  
Ammonium sulphate  Roth, Germany 
Ampicillin Sigma, Germany 
Ascorbic acid Applichem, Germany  
Bromophenol blue Merck, Germany 
Calcium carbonate Merck, Germany 
Calcium chloride Applichem, Germany  
Chloramphenicol Roth, Germany 
Chloroform Roth, Germany 
Choline chloride Applichem, Germany  
Coomassie brilliant blue Applichem, Germany 
Crystal violet Sigma, Germany 
Deoxynucleotide-triphospate (dNTPs)  Rapidozym, Germany 
Dimethylethanolamine Sigma, Germany 
Dimethyl sulfoxide (DMSO)  Sigma, Germany 
DNA marker (1 kb ladder) Fermentas, Germany 
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Dragendorff's reagent Sigma, Germany 
Distilled water (HPLC-purified) Roth, Germany 
Dithiothreitol (DTT) Applichem, Germany 
Dubecco’s Modified Eagle Media (DMEM)  
(w/o Na-pyruvate, w/o L-glutamine,  
4.5 g/l D-glucose) 
Biochrom, Germany 
EDTA Applichem, Germany 
Ethanol Applichem, Germany 
Ethanolamine chloride Applichem, Germany 
Ethidium bromide   Applichem, Germany 
Fetal calf serum Biochrom, Germany  
Fluoromount G / DAPI SouthernBiotech, USA 
5-Fluoro-2’-deoxyuridine (FUDR) Sigma, Germany 
Glacial acetic acid (99 %) Applichem, Germany 
D(+)-Galactose Applichem, Germany 
α-D(+)-Glucose monohydrate Applichem, Germany 
Glutathione Applichem, Germany 
Glycerol Applichem, Germany 
Human Serum (1 unit) Interstate Blood Bank, Memphis, TN, USA 
Iodine (anhydrous beads) Sigma, Germany 
IPTG Applichem, Germany 
L-glutamine (200 mM) Biochrom, Germany 
Lipofectamine 2000  Invitrogen, USA 
Lithium acetate Applichem, Germany 
Mangan(II)-chloride-tetrahydrate Applichem, Germany 
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Magnesium chloride hexahydrate Applichem, Germany 




Mycophenolic acid Applichem, Germany 
NADH, Disodium salt Calbiochem, Germany 
Na-pyruvate (100 mM) Biochrom, Germany 
NBD-labeled phospholipids  Avanti Polar Lipids, USA 
Non-essential amino acids (100x) Biochrom, Germany  
Paraformaldehyde Roth, Germany 
PBS Biochrom, Germany 
Penicillin / Streptomycin Biochrom, Germany 
Penicillin / Streptomycin Invitrogen, Germany 
Perchloric acid Applichem, Germany 
Phosphocholine Sigma, Germany 
Phosphoethanolamine Sigma, Germany 
Polyethylenglycol 3350 Applichem, Germany 
Potassium acetate Roth, Germany 
Potassium chloride Roth, Germany  
Potassium dihydrogen phosphate Applichem, Germany 
Potassium hydrogen carbonate Applichem, Germany 
Di-potassium hydrogen phosphate Applichem, Germany 
Potassium hydroxide Merck, Germany 
Potassium sulphate Applichem, Germany 
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Protein marker (prestained) New England Biolabs, Germany 




Rotiphorese Gel 30 Roth, Germany 
Phosphoenolpyruvate Applichem, Germany 
Primers (see Table 1)  Invitrogen, Germany 
Pyrimethamine Sigma, Germany 
Pyruvate kinase/Lactic dehydrogenase  Sigma, Germany 
Salmon sperm DNA (10 mg/ml) Invitrogen, Germany 
Salts Roth, Applichem, Germany 
Sodium dodecyl sulfate (SDS) Roth, Germany 
TEMED Roth, Germany 
TLC plates (silica 60) VWR, Germany 
Tris-HCl Applichem, Germany  
Triton X-100 Applichem, Germany 
Trizol Invitrogen, Germany 
Trypsin / EDTA Biochrom, Germany 
Tryptone Applichem, Germany 
Xanthine Applichem, Germany 
X-Gal Applichem, Germany 
Yeast extract Roth, Germany 
Yeast nitrogen base (YNB)  Sigma, Germany 
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C]-Cytidine diphosphocholine Biotrend, Germany 
[
3
H]-Choline chloride Perkin Elmer, USA 
[
14
C]-Choline chloride Biotrend, Germany 
[1,2-
3
H]-Ethanolamine Hartmann Analytic, Germany 
Liquid scintillation cocktail  Perkin-Elmer, USA  
[
14
C]-Phosphocholine Biotrend, Germany 
24-well scintillation plate Perkin Elmer, Germany 
 
2.1.4 Vectors 
Plasmid  Source 
pcDNA3.1
+
 Isabelle Coppens, Johns Hopkins University, 
Baltimore, USA 
p2854 DFHR-TS Dominique Soldati, University of Geneva, 
Switzerland 
pDT7S4 Boris Striepen, University of Georgia, USA 
pESC-Ura, pESC-His Stratagene, USA 
pET22b
+
 Novagen, Germany  
pET28b
+
 Novagen, Germany  
pET41b
+
 Novagen, Germany  
pNTP3 Isabelle Coppens, Johns Hopkins University, 
Baltimore, USA 
pNTP3TetO7Sag1  modified pNTP3 
pTetO7Sag1-NTP3-UPKO (pTetUPKO) modified pNTP3 
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pTKO John Boothroyd, Stanford University School 
of Medicine, USA 
 
2.1.5 Antibodies and working dilutions 
Antibody and dilution factor Source 
Alexa 594, Alexa 488 (anti-mouse, anti-
rabbit) (1:3000) 
Invitrogen, Germany 
α-HA (rabbit, mouse) (1:1000) Invitrogen, Germany 
Anti-6xHis-tag mAb IgG1 (mouse) Dianova, Germany 
Phalloidin-Alexa595 Invitrogen, USA 
α-TgActin Dominique Soldati, University of Geneva, 
Switzerland 
α-TgGap45 (1:3000) Plattner et al. (46) 
α-TgGra3 (1:500)  Dubremetz et al. (47) 
α-TgSag1 (1:1000) Kim and Boothroyd (48) 
α-Ty1 (BB2 hybridoma culture supernatant, 
1:50) 
Bastin et al. (49) 
α-V5 (1:1000) John Leslie, Immunology  




Antartic phosphatase NEB, Germany 
Dream Taq polymerase Fermentas, Germany 
Pfu Ultra II Fusion HS DNA polymerase Stratagene, Germany 
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Proteinase K Sigma, Germany 
Restriction endonucleases, Klenow enzyme  NEB, Germany 
T4 ligase Invitrogen, Germany 




BioPhotometer Eppendorf, Germany 
BTX square wave electroporator (ECM 830) BTX, USA 
Gel documentation & EASY Enhanced Analysis Herolab, Germany 
Gel electrophoresis chamber and power supply  Amersham Biosciences, USA 
Microscope (Apotome Imager.Z2) Zeiss, Germany 
Nanodrop (ND 1000) Wilmington, USA 
PCR Thermocycler (FlexCycler)  JenaAnalytic, Germany 
Scintillation counter (1450 MicroBeta TriLux) PerkinElmer, USA 
TLC developing tank  Sigma, Germany 
Western Blotting chamber Peqlab, Germany 
 
2.1.8 Plasticware and disposables 
Product Manufacturer 
Cover slips Roth, Germany 
Cryo tubes Biochrom, Nalgene, Germany 
Disposable pipettes (10 ml, 25 ml, 50 ml) Greiner Bio-One, Austria 
Eppendorf tubes (1.5 ml, 2 ml) Greiner Bio-One, Austria 
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Electroporation cuvettes (4 mm gap)  Eppendorf, Germany 
Falcon tubes (15 ml, 50 ml) Greiner Bio-One, Austria 
Filter sterilizer (0.22 µm) Schleicher Schuell, Germany 
Glass beads (0.45 – 0.6 mm)   Sartorius, Göttingen, Germany 
High performance chemiluminescence film GE Healthcare, Germany 
LabTek chamber slides ThermoScientific, Germany 
Microscopy slides Menzel, Germany 
Needles BD, Germany 
Nitrocellulose transfer membrane Applichem, Germany 
Improved Neubauer counting chamber Neubauer, Germany 
Parafilm Pechiney, USA 
PCR tubes  Rapidozym, Germany 
Pipette tips Greiner Bio-One, Austria 
Polypropylene tubes (12 ml)  Greiner Bio-One, Austria 
RNAase-free barrier tips Sorenson BioScience, USA 
Syringes BD, Germany 
Tissue culture flasks, Petridishes, Multi-well 
plates  
Greiner Bio-One, Austria 
Whatman (3 MM) A. Hartenstein, Germany 
X-ray film (FUJI Medical) A. Hartenstein, Germany 
 
2.1.9 Commercial kits 
Product Manufacturer 
DNA purification (plasmid preps) Jena Analytic, Invitrogen, Germany 
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pDrive cloning kit  Qiagen, Germany 
ECL Western blotting and analysis system GE Healthcare, Germany 
µMACS mRNA isolation  Miltenyi Biotec, Germany 
µMACS one-step cDNA synthesis Miltenyi Biotec, Germany 
Platinum SYBR Green qPCR Superscript-
UDG 
Invitrogen, Germany 
Protein Assay Kit (BCA) Thermo Scientific, USA 
Pure Link RNA Mini Kit Ambion, Germany 
Reverse transcription PCR (SuperScript III)  Invitrogen, Germany 
SuperScript III First-strand synthesis 
supermix for qRT-PCR 
Invitrogen, Germany 
 
2.1.10 Reagent preparations 
Solution Composition 
D10 DMEM (high glucose) supplemented with 
10% FCS, 2 mM L-Glutamine, 1x NEAA, 1 
mM Sodium pyruvate, 100 U/ml Penicillin 
and 100 µg/ml Streptomycin   
LB media 
 
10 g tryptone, 5 g yeast extract and 10 g 
NaCl in 1 liter ddH2O (15 g of agar-agar 
optional for plates) 
SOB media 
 
20 g tryptone, 5 g yeast extract, 0.5 g NaCl, 




2% tryptone (w/v), 0.5 % yeast extract (w/v), 
10 mM NaCl, 2.5 mM KCl  and 20 mM 
glucose in ddH2O  
 34 
TFB I 30 mM KOAc (pH 5.8), 50 mM MnCl2 x 4 
H2O, 10 mM CaCl2, 100 mM RbCl, 15% 
glycerol 
Filter sterilize 
TFB II 10 mM MOPS (pH 7), 75 mM CaCl2, 10 mM 




20 g peptone, 10 g yeast extract and 20 g 
agar-agar (optional) in 950 ml ddH2O. Filter-
sterile glucose (40% stock) was added to 
obtain a final concentration of 2% 
10x amino acid mix 
 
adenine hemisulfate (400 mg), L-Arg (200 
mg), L-Asp (1000 mg), L-Gln (1000 mg), L-
His (200 mg), L-Leu (600 mg), L-Lys (300 
mg), L-Met (200 mg), L-Phe (500 mg), L-Ser 
(3750 mg), L-Thr (2000 mg), L-Try (400 
mg), L-Tyr (300 mg), L-Val (1500 mg) and 
Uracil (200 mg) in 500 ml ddH2O. Uracil or 
histidine was omitted for selective media. 
Synthetic drop-out media 
 
1.7 g YNB (free of ammonium sulphate and 
amino acids) and 5 g ammonium sulphate in 
500 ml ddH2O. The 10x amino acid mix and 
40% sugar (final 2 %) stocks were added to 
obtain synthetic drop-out media 
Cytomix for T. gondii transfection 
 
120 mM KCl, 0.15 mM CaCl2, 100 mM 
K2HPO4/KH2PO4, 500 mM HEPES, 100 mM 
EGTA and 100 mM MgCl2. 30 µl ATP (100 
mM stock), 12 µl GSH (250 mM stock) and 
10-50 µg DNA were added to 700 µl prior to 
the parasite transfection 
Transformation buffers for S. cerevisiae 10x TE buffer 
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 100 mM Tris (pH 7.5), 10 mM EDTA 
Buffer was filter sterilized and stored at 4°C. 
The 1x TE buffer was freshly prepared from 
10x TE buffer. 
 LiAc / TE buffer 
The 1x LiAc / TE buffer was prepared by 
diluting 10x LiAc (1 M lithium acetate, pH 
7.5) and 10x TE solutions in sterile water. 
 PEG3350 / LiAc / TE buffer 
This solution was prepared fresh from 10x 
TE, 10x LiAc and filter-sterilized PEG3350 
(50 %, w/v) in a ratio of 1:1:8. 
TAE buffer for agarose gel electrophoresis 
 
The 1x TAE buffer was prepared from 50x 
buffer, which contained 242 g/l of Tris base, 
57.1 ml/l of glacial acetic acid and 18.6 g/l of 
EDTA. 
Lysis buffer for genomic DNA 
 
10 mM Tris-HCl (pH 8), 5 mM EDTA, 0.5% 
SDS, 200 mM NaCl in ddH2O. 100 µg/ml 
proteinase K solution was added prior to use. 
Choline/Ethanolamine kinase assay solutions  
 
Assay buffer (1x) 
ATP (10 mM), DTT (1.3 mM), MgCl2 (11 
mM), Tris (67 mM, pH 8.5)  






choline chloride or [1,2-
3
H]-ethanolamine 
chloride + ethanolamine chloride prior to use  
 Prepare 100 mM choline chloride stock in 
ddH2O 
 Prepare 100 mM choline chloride stock in 
0.5 N NaOH for ammonium reineckate 
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precipitation and dilute (final 10 mM and 40 
mM choline chloride) prior to use  
 Prepare 5 M ethanolamine chloride stock in 5 
M HCl for ethanolamine kinase assay 
 Prepare 5 M dimethylethanolamine chloride 
stock in 5 M HCl for choline kinase 
inhibition 
 5 % Ammonium reineckate salt in methanol  
(prepare fresh) 
 
2.1.11 Primer Table 1 
Primer Name  
(restriction site) 
Primer Sequence  
(restriction site underlined) 
Cloning Vector  
(research objective)  
   
Functional Expression in E. coli 
TgCK-F (NdeI) CTCCATATGCAGGTACTCGCGTGTGT 





TgCK-wo-HP-F (NdeI) CTCATCCATATGTCCCCTTCAGGCGCTGGCT 





TgEK-F (NcoI) CTCCCATGGCCAGCAAGGCAGAGAGAAC 
TgEK-R (HindIII) CTCAAGCTTGAACGACAAATGCGGGACT 
pET28b
+
 (TgEK-6xHis in 
Rosetta strain) 
TgCCT-F1 (NdeI) CTCATCCATATGGAGGCTGTTAGCAGTTCTTC 













TgEPT-F1 (NdeI) CTCATCCATATGGTGTTTGGACACTACATTCCCCCT pET41b
+
 (TgEPT-6xHis in 
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TgEPT-R1 (NotI) CTCATCGCGGCCGCAGCCCCGCGCCGTCTGCT Rosetta strain) 
Functional Expression in S. cerevisiae 




pESC-Ura (ScCK1 in 
KS106 strain) 
ScEK1-F (SpeI) CTCACTAGTATGTACACCAATTATTCACTTAC 
ScEK1-R (BglII) CTCAGATCTTTAAAAAATAAGTTTAGTGTCTAAG 








pESC-His (TgCCT in 
Y04832 or Y04637 strain) 




pESC-His (TgCPT in 





TgEPT-R2 (NotI) CTCATCGCGGCCGCCTAAGCCCCGCGCCGTCT 
pESC-His (TgCPT in 
Y04832, Y04637 or HJ000 
strain)  




















pESC-His (ScECT1 in 
Y04637 strain) 
ScEPT1-F (NotI) CTCATCGCGGCCGCATGGGATATTTTGTTCCGGATT 
ScEPT1-R (NotI) CTCATCGCGGCCGCTTATGTCAGCTTGGAGCGC 
pESC-His (ScCPT1 in 
HJ000 strain) 
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Subcellular Localization in T. gondii 
TgCK-Term-F (HindIII) CTCAAGCTTCTGGAATTTGGAGTCAACGC 
TgCK-Term-R (NheI) CTCGCTAGCCAAGCAGAAGTCGGATATTAGCG 
Step # 1 for expressing 
TgCK-HA under the 
pTgCK promoter in 
tachyzoites 
TgCK-Prom-F (ApaI) CTCGGGCCCGGCAGGTGGTTTTGCTTC 
TgCK-Prom-R (HindIII) CTACTGAAGCTTGAATACTCTCGAAC 
Step # 2 for expressing 
TgCK-HA under the 
pTgCK promoter in 
tachyzoites 





Step # 3 for expressing 
TgCK-HA under the 










Step # 1 for expressing 
TgCK-Ty1 under the 









Step # 2 for expressing 
TgCK-Ty1 under the 
pTgCK promoter in 
tachyzoites 




pTKO (For expressing 
TgCKS-myc in 
tachyzoites) 




pNTP3 (For expressing 
TgEK-HA in tachyzoites) 






(TgCCT-HA under the 
pTetO7Sag1 promoter in 
tachyzoites) 





(TgCPT-HA under the 
pTetO7Sag1 promoter in 
tachyzoites) 
Functional Expression in COS-7 Cells 
TgCK-F4 (HindIII) CTCATCAAGCTTATGCAGGTACTCGCGTGTGT 




under the pCMV promoter 
in COS-7 cells) 
TgCCT-F4 (HindIII) CTCATCAAGCTTATGGAGGCTGTTAGCAGTTCTTC 




under the pCMV promoter 
in COS-7 cells) 







under the pCMV promoter) 








under the pCMV promoter 
in COS-7 cells) 









displacement of TgCK in 








displacement of TgCK in 
the TaTi-∆ku80 strain) 
TgCK-PD-5’Scr-F CATTCCGAGGCGGATAAA 
DHFR-R CGGGTTTGAATGCAAGGTT 
Screening for 5’-crossover 




Screening for 3’-crossover 
in transgenic TaTi-∆ku80 
strain 









(conventional knockout of 











(conventional knockout of 






Screening of 5’-crossover 






Screening of 3’-crossover 


























Screening of 5’-crossover 




Screening of 3’-crossover 
in transgenic TaTi-∆ku80 
strain 
Quantitative PCR of TgCK 
TgCK-Ex1-F1 TAAAGGGCTGGGAAAACCTT 
TgCK-Ex1-R1 CTCTTGCCTCGAATTTCCAC 
qPCR of Exon1 (368-576 




qPCR of Exon1 (80-360 
bp) in TgCK transcript 
TgCK-Ex6-F TCTTCTCCGTCCACTTGACC 
TgCK-Ex6-R GTCCACCATAGCCTTGGAAA 
qPCR of Exon6 (1547-












2.2  Methods - Culture and Transfection 
2.2.1 Propagation of mammalian cells 
The primary human foreskin fibroblasts (HFF) were cultured in Dulbecco’s modified Eagle’s 
medium with 10% fetal calf serum, 2 mM glutamine, 1x MEM non-essential amino acids, 100 
units/ml penicillin and 100 µg/ml streptomycin in a humidified incubator (37°C at 10% CO2). 
The cells were harvested using Trypsin/EDTA and seeded into flasks and dishes.  
 
2.2.2 Propagation of Toxoplasma gondii tachyzoites 
All strains of T. gondii tachyzoites were maintained by serial passage in confluent HFF 
monolayers. Transgenic parasites were selected in 25 µg/ml mycophenolic acid (MPA) with 
50 µg/ml xanthine or 1 µM pyrimethamine or 5 µM FUDR. The tranfected parasites were 
added to the host monolayer and allowed to invade. Selection with pyrimethamine or MPA 
and xanthine was started 12-24 hrs post-transfection by adding fresh medium containing the 
indicated amounts of the respective drugs. Medium was then changed and fresh drug was 
added every day and after about 1 week stable transgenic parasites were obtained. For 
selection with FUDR, transfected parasites were passaged for 4 cycles in medium without 
drug. Then, D10 medium supplemented with 5 µM FUDR was added to the intracellular 
parasites. Fresh medium containing drug was added after 1 week, and the cultures were 
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incubated for 2 weeks or until the lysed-out vacuoles were observed. The stable parasites were 
pooled and subjected to cloning by limiting dilution.  
 
2.2.3 Transfection of T. gondii tachyzoites 
Freshly egressed or syringe-released parasites (10 to 30x10
6
) were centrifuged at 300 g for 10 
min at RT, washed once in 1x PBS, and the pellet was suspended in 700 µl of cytomix. This 
mixture was complemented with 5-50 µg of linearized or circular plasmid DNA, 30 µl ATP 
(sterile 100 mM stock) and 12 µl GSH (sterile 250 mM stock). Electroporation was done by 
two 1.7 kV pulses at an interval of 100 msec using a BTX square wave electroporator. 
Transfected parasites were used to infect confluent HFF monolayers for further experiments.  
 
2.2.4 Transformation of Saccharomyces cerevisiae 
The YPM media containing 2 % glucose (50 ml) was inoculated (OD600 of 0.1) with an over-
night-grown pre-culture of S. cerevisiae and grown at 30°C with shaking until an OD600 of 0.4 
was reached. Yeast cells were pelleted by centrifugation (1000g, 5 min, RT), followed by 1x 
washing with 25 ml of sterile TE-buffer and then with 10 ml of LiAc / TE buffer. The final 
pellet was resuspended in N*100 µl of LiaAc / TE buffer (N number of transformations) and 
incubated at RT for 30 min. 100-200 ng of plasmid preparation and 100 µg of salmon sperm 
DNA were added to the 100 µl of competent yeast suspension and mixed by finger tapping. 
The 0.6ml of PEG / LiAc / TE (8:1:1) solution was added to the transformation mix followed 
by vortexing for 10 seconds and horizontal incubation for 30 min (200 rpm, 30°C). Then, 70 
µl of DMSO were added to each reaction and the suspension was mixed by inverting the tube. 
A heat-shock was performed for 15 min at 42°C in water bath followed by immediate cooling 
on ice for 2 min. Cells were pelleted at 14000 g for 15 sec and washed with 1x TE buffer prior 
to suspension in 100 µl of TE buffer. Finally, cells were plated on selective SD plates (-ura or 
-his) with 2 % glucose and incubated at 30°C for three to four days. One colony was picked 
from each plate and streaked onto a master plate for subsequent experiments. Freezer stocks 




2.3  Methods - Molecular Cloning 
2.3.1 PCR reactions 
10-500 ng of the template DNA was used for PCR. The Dream-Taq polymerase (Fermentas) 
was employed for standard analytical PCR, and the Pfu-Ultra FusionII high-fidelity 
polymerase (Stratagene) was used for expression cloning. PCR composition and conditions 
were set according to the primers, polymerase and the length of amplification targets. The 
PCR reaction was tested for amplification using 0.8-1% agarose gel with0.4% ethidium 
bromide ran in 1x TAE buffer. The DNA product was mixed with 6x loading dye and resolved 
at 80-100V followed by UV-visualization.  
 
2.3.2 Ligation of DNA 
The PCR amplified inserts were evaluated for their purity on  agarose gel and subsequently 
purified either by gel extraction or by column purification according to the kits’ manual. The 
vector DNA was isolated from E. coli according to the kits’ protocol (plasmid miniprep) and 
concentration was determined by NanoDrop instrument. Insert and plasmid were subjected to 
digestion with appropriate restriction enzymes. In case of non-directional gene cloning, prior 
to ligation, the plasmid was dephosphorylated using Antartic Phosphatase (NEB) for 1 hr at 
37°C followed by heat inactivation (65°C, 30 min). Digested vector and insert were mixed in 
molar ratios of 1:3 or 1:5 (10 fmol of vector and 30 or 50 fmol of insert) and ligated using 1U 
of T4 ligase (1 hr at RT or at 4°C over-night), prior to transformation of the competent E. coli 
(Xl1-blue) cells.  
 
2.3.3 Competent Escherichia coli cells 
A 5 ml over-night-grown culture of E. coli (XL-1blue or the Rosetta strain) was used to 
inoculate 200 ml SOB culture, which was grown at 37°C until an OD600 of 0.4 to 0.5 was 
reached. The culture was pelleted (1300 g, 10 min, 4°C) and washed once in 50 ml of ice-cold 
TFB-I buffer. Cells were resuspended in 6.4 ml of TFB-II buffer and snap-frozen into aliquots 
at -80°C.  
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2.3.4 Transformation of Escherichia coli 
Each ligation reaction was mixed with a 10-fold higher volume of freshly-thawed competent 
E. coli. The samples were incubated on ice for 30 min, followed by a heat shock (45 sec, 
42°C), and 2 min cooling on ice. Prewarmed SOC media (750 µl) was added to each 
transformation reaction and the mix was shaked at 37°C for 1 hr. The cells were pelleted (3 
min, 6000 rpm), resuspended in fresh LB media and plated on Amp or Kan plates according 
to the plasmid. The plates were incubated at 37°C overnight.   
 
2.3.5 Purification of recombinant proteins from Escherichia coli 
The full-length choline kinase (TgCK) and ethanolamine kinase (TgEK) proteins with a C-
terminal 6xHis tag (TgCK-6xHis, TgEK-6xHis) and a truncated TgCK lacking its first 20 
residues with an N-terminal histidine tag (6xHis-TgCKS) were cloned in the pET22b
+
(TgCK-
6xHis) or in the pET28b
+
(TgEK-6xHis, 6xHis-TgCKS) plasmids, and expressed in the E. coli 
Rosetta strain. The cultures were grown at 37°C until an OD600 of 0.3-0.5 was reached, and 
induced with 1 mM IPTG for 4 hrs at 25 °C. Cells were pelleted (5000xg, 10 min, 4 °C), and 
suspended in 6 ml of binding buffer (20 mM NaH2PO4 (pH 7.4) with 500 mM NaCl, 10 mM 
imidazole, 10% glycerol and protease inhibitors). Samples were lysed by probe sonication (3 
phases, 30sec each), and the cell debris was removed (5000xg, 10 min, 4°C). The cell-free 
extracts were re-centrifuged (15000xg, 30 min, 4 °C), and the supernatant was used to 
affinity-purify TgEK-6xHis, TgCK-6xHis and 6xHis-TgCKS proteins using the Ni-NTA resin 
(Qiagen) and 20 mM NaH2PO4 (pH 7.4), with 500 mM NaCl and 100 mM imidazole. Purified 
proteins were concentrated using 50-kDa cut-off centrifugal filters (Amicon), and quantified 
by Bradford method (50). 
 
2.3.6 Nucleic acid preparation 
The genomic DNA was prepared from lysed-out T. gondii tachyzoites according to Rotureau 
et al. (51). Briefly, the cell pellet was lysed in 200 µl of lysis buffer and incubated for 30 min 
at 65°C prior to precipitation with 450 µl of absolute cold ethanol. The DNA pellet was dried 
at RT and dissolved in sterile water. 
To prepare the RNA, RNAase-free material was used throughout the procedure. Toxoplasma 
gondii-infected cells were washed with PBS and dissolved in 1 ml of Trizol and stored at -
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80°C until use. The sample was thawed and RNA was isolated using the Pur Link RNA Mini 
kit according to the kit`s protocol. In brief, 200 µl of CHCl3 were added to each sample and 
the tubes shaked by hand for 15 seconds, followed by incubation at RT for 2 min. Phase 
separation was achieved by centrifugation (12000 x g, 15 min, 4°C) and 400 µl of the upper 
RNA-containing phase were transferred to a fresh RNase-free tube. An equal volume of 70% 
ethanol was added, the mixture was transferred to a spin cartridge and subsequently 
centrifuged at 12000 x g for 15 seconds and RT. An on-column DNase I treatment was 
performed for 15 min at RT, prior to two washing steps and elution of the RNA in RNAase-
free water. The RNA isolated by this method was used for quantitative PCR. For expression 
cloning, mRNA was isolated from fresh syringe-released tachyzoites and transcribed into 
first-strand cDNA using the µMACS mRNA isolation and the cDNA synthesis kits (Miltenyi 
Biotec, Germany). The cDNA was synthesised using SuperScript III first-strand cDNA 
synthesis kit (Invitrogen) using oligo-dT primers and stored at -20°C. Subsequent 
amplification of specific ORFs was performed using Pfu-Ultra FusionII high fidelity 
Polymerase (Stratagene, Germany) and the indicated cDNA-specific primers (Primer Table 1). 
 
 
2.4  Methods – Assays 
2.4.1 Indirect immuno-fluorescence assay (IFA) 
The HFF were grown on glass coverslips in a 24-well plate and infected with parasites. The 
parasite-infected cells were fixed with 2% paraformaldehyde (PFA) for 15 min at RT, 
followed by 5 min neutralization in 0.1 M Glycine/PBS. Cells were permeabilized in 0.2% 
Triton-X100/PBS for 20 min, and non-specific binding was blocked with 2% BSA in 0.2% 
Triton-X100. Samples were stained with primary antibodies (anti-TgGap45 1:3000; anti-
TgCK serum 1:200; anti-HA 1:1000; anti-Ty1 1:50; anti-Myc 1:1000, anti-V5 1:1000 
dilutions) followed by three washes with 0.2% Triton-X100 in PBS. Finally, the 
corresponding secondary antibodies (mouse or rabbit Alexa488 or Alexa594) were applied 
(1:3000), and after three PBS washes slides were mounted in DAPI-Fluoromount G for 
fluorescent imaging (Apotome, Carl-Zeiss, Germany). Pictures were taken at 63x 
mgnification using filtersets 38HE eGFP (green), 43HE Cy3 (red) and 49 DAPI (blue) and 
processed with the Axiovision software (Carl-Zeiss).  
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2.4.2 Immuno-electron microscopy (IEM) 
T. gondii-containing fibroblasts were fixed with 4% PFA (Electron Microscopy Sciences, PA) 
in 0.25 M HEPES (pH 7.4) for 1 hr at RT and then with 8% PFA in the same buffer overnight 
at 4°C. They were infiltrated, frozen and sectioned as previously described (52) In brief, cell 
preparations were scraped, pelleted, and embedded in 10% bovine skin gelatin in PBS. The 
pellet sections were infiltrated overnight with 2.3 M sucrose in PBS at 4°C, mounted on 
aluminum studs, and frozen in liquid nitrogen. Samples were sectioned at -108°C using a 
cryo-ultramicrotome (Leica). The 60-nm thick sections were collected using a mixture of 2.3 
M sucrose and 2% methyl cellulose (1:1) and then transferred onto formvar- and carbon-
coated nickel grids. Ultrathin sections were incubated with 0.1 M NH4Cl in PBS for 10 min 
and then with 0.5% fish skin gelatin in PBS for 20 min. The sections were immuno-labeled 
with mouse anti-TgCK antiserum (1:250 in PBS/1% fish skin gelatin), and then with anti-
mouse IgG antibody, which was immediately followed by 10 nm protein A-gold particles 
(Department of Cell Biology, Medical School, Utrecht University, Netherlands). Samples 
were examinated with a Philips CM120 Electron Microscope (Eindhoven, Netherlands) under 
80 kV. For double immuno-staining, the sections were labeled with the mouse anti-TgCK 
antiserum revealed by 10 nm protein A-gold particles, and the rat anti-HA antibody (1:200) 
detected by 5 nm protein A-gold particles.  
 
2.4.3 Plaque and replication assays 
Plaque assay recapitulates all events of the parasite’s lytic cycle including host cell invasion, 
intracellular replication, and re-invasion of neighboring cells. HFF cells in the 6-well plates 
were infected with 200 tachyzoites, cultured for 7 days without perturbation, fixed with -80°C 
methanol and stained with crystal violet for 10 min followed by 2x washing with PBS. The 
images were documented at 4x magnification using an inverted Leica microscope. The mean 
area of the plaque images from three independent biological replicates (50 plaques each) was 
calculated for evaluating the parasite growth. For replication assays, HFFs grown on glass 
coverslips were infected with parasites (MOI=3) and subjected to IFA using anti-TgGap45 
(1:3000) antibody 29 hrs post-infection. The parasite replication was deduced from the 
number of parasites in their vacuoles. The three independent experiments each with 50 
vacuoles were performed. 
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2.4.4 Radioactive and photometric choline kinase assays 













C]-choline (2.5 nCi/nmol; 0.25 
nCi/nmol) and increasing concentrations of choline chloride (0-3.2 mM) were mixed with 5x 
reaction buffer (final concentrations 67 mM Tris-Cl (pH 8.5), 10 mM ATP, 11 mM MgCl2, 1.3 
mM DTT) in a total volume of 60 µl. The 0.2-2 µg of cell-free extract or purified protein were 
added and the reaction mix was incubated at 37°C for 4 min following. Initial optimization 
assays had confirmed a linear enzyme activity in this range. The reaction was stopped by 
adding 20 µl of 10 mM choline chloride prepared in 0.5 N NaOH. The residual substrate was 
then removed from the radiolabeled product (phosphocholine) as choline reineckate by 
precipitation with 50 µl ammonium reineckate (250 mg in 4-5 ml CH3OH) (53). The reaction 
products were separated on silica gel 60 plates using the solvent system containing 95% 
ethanol/2% ammonium hydroxide (1:1). The activity was determined by phospho-imaging 
and quantified by scintillation counting.  
To study the inhibitory effect of DME on TgCK, the formation of radioactive phosphocholine 
from [
3
H]-choline was monitored in the presence of a constant concentration of choline (2.5 
nCi/nmol, 0.2 mM) and increasing amounts of DME (0-4 mM).  The reactions were run for 4 
min at 37 °C in water bath. Residual choline was precipitated as reineckate salt and the 
amount of [
3
H]-phosphocholine was determined by radioactive scintillation counting. To 
study the mechanism of inhibition, the TgCK assay was performed with purified enzyme in 
the absence or presence of 2 mM DME, and the formation of phosphocholine was quantified 
by scintillation counting.  
A similar assay was performed with [
3
H]-ethanolamine. 5 µl of [1,2-
3
H]-ethanolamine (50 
nCi/nmol) were dissolved in 100 µl of 1 mM ethanolamine chloride. 10 µl of this suspension 
was mixed with the 5x choline kinase buffer and purified protein (as described above) in a 
total volume of 100 µl. Reactions were incubated for 30 min at 37°C and then terminated by 
10 µl of glacial acetic acid. The product formation was evaluated by TLC without any 
precipitation.  
Choline kinase was also assayed by a spectrophotometric method adapted from a pyruvate 
kinase/lactate dehydrogenase-coupled system (54). The phosphorylation of choline by an 
active choline kinase produces ADP, which reacts with phosphoenol-pyruvate to form 
pyruvate and ATP, a reaction catalyzed by pyruvate kinase. Finally, the lactate dehydrogenase 
converts pyruvate into lactate, thereby oxidizing NADH to NAD
+
. A choline-dependent 
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decrease in the NADH absorption (340 nm) represents the enzyme activity of choline kinase. 
The 200-µl reaction in a 96-well plate contained indicated amounts of choline, 100 mM Tris-
Cl (pH 8.5), 100 mM KCl, 10 mM MgCl2, 0.4 mM NADH, 5 mM ATP, 1 mM phosphoenol-
pyruvate, pyruvate kinase (30 U), lactate dehydrogenase (37 U) and purified protein (1-2 µg). 
The choline-independent ATPase activity of choline kinase was recorded and subtracted from 
the choline-dependent ATP turnover. To measure the steady-state kinetics, one substrate was 
kept constant (5 mM ATP; 4 mM choline or DME), whereas the other was varied (0–4 mM 
choline or DME). Data were fitted to the Michaelis-Menten equation using a robust fit 
nonlinear regression (GraphPad Prism v5.0).  
 
2.4.5 Genetic manipulation of the TgCK gene 
The TgCK promoter was displaced using a tetracycline-regulatable promoter (pTetO7Sag4). 
Primers used for the genetic manipulation are depicted in Primer Table 1 (page 36). The 
5’UTR fragment (2-kb), amplified from tachyzoite gDNA using the primers (TgCK-PD-
5’UTR-F/R), was cloned into the pDT7S4 vector at the NdeI site. The 1-kb region 
downstream to the initiating ATG of the TgCK gene was amplified (primers TgCK-PD-
3’UTR-F/R), and cloned at BglII and AvrII to achieve the promoter-displacement construct. 
The TaTi-∆ku80 strain of T. gondii was transfected with 50 µg of the linearized construct 
(ApaI) using the BTX630 instrument (1.7 kV, 50 Ohm, 25 µF, 100 µs), and stable transgenic 
parasites were selected with 1 µM pyrimethamine (16). The drug-resistant parasites were 
apparent within ~2 weeks, which were cloned by limiting dilution in the 96-well plates, and 
screened for 5’- and 3’-recombination using TgCK-PD-5’Scr-F/DHFR-R or DHFR-F/TgCK-
PD-3’Scr-R primers. The knockout of TgCK was attempted using p2854-DHFR-TS vector 
containing about 3.3-kb of 5’- (HindIII/NheI) and 3’-UTR (NotI/NotI) sequences flanking the 
DHFR-TS resistance cassette. The ApaI- or PsiI-linearized construct was transfected in -
∆ku80 or hxgprt- strain, and the parasites were selected using pyrimethamine (16). The 
transgenic parasites were cloned, and screened using 5’- and 3’-crossover-specific primers 
(TgCK-KO-5’Scr-F/DHFR-R2 or DHFR-F2/TgCK-KO-3’Scr-R). 
 
2.4.6 Genetic manipulation of the TgCCT gene 
A tetracycline-regulatable copy of the C-terminally HA-tagged TgCCT ORF (TgCCTi-HA) 
was inserted at the TgUPRT locus via double homologous recombination. To generate the 
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construct, the TgCCT cDNA (987 bp) was amplified from the tachyzoite mRNA using 
primers TgCCT-F3/-R3 and digested with EcoRV and PacI. The vector pTetUPKO was first 
digested with NcoI followed by treatment with Klenow enzyme and PacI digestion for blunt-
cohesive ligation of the TgCCTi-HA ORF. The NotI-linearized construct was transfected into 
TaTi-∆ku80 strain, and the resistant parasites were selected with 5µM FUDR. The expression 
and tetrycycline regulation of TgCCT-HA was confirmed by IFA using the mouse anti-HA 
antibody (1:1000). The p2854-DHFR-TS plasmid was modified to generate a knockout 
construct to subsequently delete the endogenous TgCCT locus. The 1 kb of the 5’- and 3’-
UTR fragments were amplified using the TgCCT-KO-5’UTR-F/-R and TgCCT-KO-3’UTR-
F/-R primers. The inserts were cloned at the ApaI/ApaI and XbaI/NotI sites of p2854-DHFR-
TS, respectively, flanking the DHFR-TS resistance cassette. The construct (50 µg) was 
linearized with NotI prior to transfection into tachyzoites. Stable selection was achieved using 
1 µM pyrimethamine within 12 days (16) and 20 clones were screened for homologous 
crossover at the TgCCT locus by genomic PCR using the crossover-specific primers (TgCCT-
KO-5’Scr-F/DHFR-R and DHFR-F/TgCCT-KO-3’Scr-R). 
 
2.4.7 Precursor labeling and lipid analyses 
Choline labeling (0.1 µCi/ml media) of intracellular parasites was performed for 40-hrs in the 
parasitized HFF (MOI of 3) cultures. Total lipids were extracted from PBS-washed axenic 
parasites according to Bligh and Dyer (55). Briefly, the 1-ml parasite suspension in PBS was 
mixed with 1.1 ml each of CH3OH and CHCl3 followed by 10 min incubation at room 
temperature to allow the phase separation. The resultant chloroform phase was washed 3 
times with 1.9 ml of CH3OH/0.2 M KCl/CHCl3 (10:9:1, v/v). The final chloroform phase 
containing lipids was dried in vials, and the radioactivity was quantified by liquid scintillation 
method. Alternatively, lipids were dried and suspended in 100 µl of CHCl3 for the TLC 
analysis on silica gel H plates in CHCl3/CH3OH/H2O (65:25:4, v/v). Lipids were visualized 
by iodine staining and/or radiographic imaging. All lipids were identified based on their co-
migration with standards. 
The chemical amounts of phospholipids were determined by lipid phosphorous assay. 
Freshly-egressed tachyzoites were washed twice with PBS and counted. The samples were 
normalized to the number of parasites and subjected to lipid extraction (55), followed by TLC 
in CHCl3/CH3OH/H2O (65:25:4, v/v). Lipids in silica gel were scraped off from iodine-
stained plate into glas vials. In addition, a phosphate standard was prepared from sodium 
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phosphate (Na2HPO4, 0-40 nM) and 40 µl of the individual concentrations were pipetted into 
fresh glass tubes. Then, 180 µl of perchloric acid (70%) were added to each tube, which were 
incubated at 200°C for 30 min with a marble put on top. The tube walls were rinsed with 
phosphate-free water (1040 µl for samples, 1000 µl for the standards) followed by addition of 
200 µl ammonium molybdate (2.5%, w/v) and 200 µl of the fresh ascorbic acid (10%, w/v), 
with gentle vortexing after each step. Subsequently, the solution was incubated in the water 
bath (15 min, 50°C), and the lipid phosphorous content was quantified by spectrometry (820 
nm).  
 
2.4.8 Preparation of LDLconjugated with NBD-phospholipids 
The C6-NBD-phospholipids were conjugated to human LDL-particles. 50 µl of the individual 
C6-NBD-phospholipids (PtdCho 8.5 mg/ml; PtdEtn 8.03 mg/ml; PtdSer 11.5 mg/ml) were 
mixed with 10 ml of fresh human serum and incubated overnight at 37°C. The NBD-lipid-
conjugated LDL was isolated by zonal density-gradient ultracentrifugation as described before 
(56). The density was adjusted to 1.25 g/ml with KBr followed by 16 hrs centrifugation 
(40000 rpm, 4°C). The lipoprotein fraction in the interphase was transferred to a fresh tube 
and the density was adjusted to 1.3 g/ml with KBr. The lipoproteins were then added to the 
bottom of centrifugation tubes containing 0.9% NaCl (ratio of 1 ml lipoproteins and 7 ml 
NaCl) followed by 4-6 hrs centrifugation (50000 rpm, 4°C). The upper orange phase 
containing the LDL-particles was transferred to a fresh tube, buffer-exchanged against PBS, 
and stored at 4°C in N2-flushed vials.   
To test for the trafficking of host LDL-derived phospholipids to the Toxoplasma membranes, 
HFF monolayers on glass coverslips in a 24-well plate grown in lipoprotein-deficient serum 
were infected (MOI = 3), and 0.1 mg/ml of the NBD-loaded LDL were added to the cultures 
28 hrs post infection. Samples were fixed after 1 hr incubation at 37°C, and lipid transport 
was analyzed by fluorescence microscopy.  
 
2.4.9 Stable transfection of COS-7 cells 
The cDNAs of TgCK, TgCCT, TgCPT and TgEPT were amplified from the tachyzoite mRNA 
and cloned at HindIII and XbaI sites in the mammalian expression plasmid pcDNA3.1
+
. The 
cloning resulted in expression of C-terminally V5-tagged proteins under the pCMV promoter. 
For transfection of COS-7 cells the BglII-linearized plasmid (4 µg) was diluted in 250 µl of 
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Opti-MEM I (Reduced Serum) Medium. Another batch of 250 µl medium was mixed with 10 
µl Lipofectamine 2000 and incubated for 5 min at room temperature. Both solutions (500 µl) 
were mixed and incubated for 20 min at room temperature. Meanwhile, a 6-well plate 
containing cultures of COS-7 cells was washed 3 times with PBS and prepared with 
antibiotic-free medium. The DNA-lipofectamine solution was added to the COS-7 cells and 
incubated at 37°C for 24 hrs. Cells were harvested by trypsine/EDTA treatment and diluted by 
at least 10-fold into T150 flasks. Selection of stable transgenic cells was started 48 hrs post-
transfection using 800 µg/µl geneticin. Medium with fresh antibiotic was changed twice a 
week until cells were confluent and stable expression of V5-tagged proteins was tested by 
IFA.  
 
2.4.10 CCT/CPT Enzyme Assay 
The enzyme activity of CCT and CPT was tested in total protein extract prepared from 
transgenic COS-7 cells, Toxoplasma (hxgprt
-
 strain) or S. cerevisiae strains Y04637, Y04832 
or HJ000 expressing TgCCT, TgCPT and TgEPT.  
To test for the CCT activity, 10 µl protein extract was incubated for 5 min at 37°C in reaction 
buffer (58 mM Tris-Cl pH 7.5, 40 mM NaCl, 1.8 mM EDTA, 8.9 mM Magnesium acetate) 
supplemented with 3 mM CTP and 0.1 µCi [
14
C]-phosphocholine (reaction volume 100 µl). 
The reaction was stopped by heat-inactivation in boiling water (2 min) and the product 
formation was analyzed by TLC (solvent 95% EtOH/2% NH4OH, 1:1) and radio-imaging. 
The CPT activity was assayed in a 200 µl reaction buffer containing 100 mM Tris-Cl (pH 8), 
20 mM MgCl2 and 1 mM EDTA. Diacylglycerol (2.5mg/ml prepared in 0.015% Tween20) 
was diluted 1:4 in the reaction buffer and supplemented with 3 mM CTP and protein extract, 
prior to 5 min pre-incubation at RT. 0.1 µCi [
14
C]-phosphocholine were added and incubated 
for 30 min at 37°C. The reaction was terminated by addition of 1.5 ml CH3OH/CHCl3 (2:1, 
v/v) followed by 0.7 ml PBS and 0.5 ml CHCl3. The organic phase was washed 3 times with 
1.8 ml of CH3OH/0.2 M KCl/CHCl3 (10:9:1, v/v) and radioactivity in the resulting lipid phase 








3.1  The Toxoplasma genome encodes enzymes of the CDP-Choline pathway 
To study the parasite CDP-choline pathway, we first searched the Toxoplasma database 
(www.ToxoDB.org) and performed protein alignments using orthologs from S. cerevisiae, P. 
falciparum and H. sapiens. Our bioinformatic analyses identified 3 putative choline and/or 
ethanolamine kinases annotated and/or expressed in T. gondii (TGGT1_120660, 
TGGT1_040800, and TGGT1_058210). Our multiple attempts to amplify TGGT1_058210 
from the tachyzoite mRNA were futile, leading to the assumption that either the gene 
annotation is incorrect or this gene might be silent in the tachyzoites. The ORFs of 
TGGT1_120660 (1.9 kb) and TGGT1_040800 (1.6 kb) were cloned using the first-strand 
cDNA prepared from the tachyzoite mRNA, which encoded TgCK and TgEK proteins with 
630 and 547 residues, respectively (Fig. 5, Appendix 1A, Appendix 2A). PCR amplification 
of the upstream flanking regions confirmed the presence of an in-frame stop codon before the 
initiating ATG in both kinases. Both ORFs harbor a choline/ethanolamine kinase domain 
(PF01633), and also contain the Brenner’s and typical choline kinase motifs. The former is a 
phosphotransferase motif, and the choline kinase motif is located downstream to the 
Brenner’s motif (57). TgCK protein shows 19%, 16% and 10% identity with HsCKα1, PfCK 
and ScCK1 with best homology observed in the conserved regions (Appendix 1B). TgEK is 
21%, 20% and 14% identical to HsEK, PfEK and ScEK1 proteins (Appendix 2B). Notably, 
TgCK possesses a peculiar N-terminal hydrophobic sequence (first 20 amino acids) with no 
homology to any known protein in the NCBI database, and long stretches of amino acid 






Fig. 5: PCR amplification of TgCK, TgEK, TgCCT and TgCPT transcripts. The tachyzoite mRNA 
was transcribed into first-strand cDNA, which was used to amplify the transcripts of TgCK (1.9 kb), 
TgEK (1.6 kb), TgCCT (1 kb) and TgCPT (1.4 kb) using the cDNA-specific primers (Primer Table 1).  
 
Our database searches also revealed annotations for a choline-phosphate cytidylyltransferase 
(TgCCT; TGGT1_098200) and a choline-phosphotransferase (TgCPT; TGGT1_013180), 
which catalyze the second and third reactions of PtdCho synthesis in T. gondii, respectively. 
Their cDNAs (TgCCT, 1 kb; TgCPT, 1.4 kb; Fig. 5), amplified from the tachyzoite mRNA, 
encode proteins of 329 and 467 amino acids, respectively (Appendix 3A, Appendix 4A). 
Mammalian cells express 2 isoforms of CCT, of which the alpha-isoform harbors an N-
terminal nuclear localization signal (NLS), whereas the CCT-beta is localized in the cytosol 
(58). The TgCCT appears proximal to the CCT-alpha with 30% and 26% identity to its human 
and yeast (S. cerevisiae) orthologs, respectively. A NLS between the amino acids 154 and 166 
of TgCCT could also be identified (red box Appendix 3A).  
TgCPT, catalyzing the fusion of the phosphocholine moiety from CDP-choline with the 
diacylglycerol (DAG) (27), displayed 20%, 19% and 26% identity to its human, yeast and 
Plasmodium orthologs, respectively (Appendix 4B). TgCPT showed best homologies to its 
orthologs in the catalytic domain (DG(X)2AR(X)8G(X)3D(X)3D) between the residues 104 
and 126 (Appendix 4B, red box). 
 
3.2 TgCK is punctate intracellular, whereas TgEK is uniformely cytosolic 
To investigate the localization of TgCK and TgEK in T. gondii, the HA- and/or Ty1-tagged 
constructs of both enzymes were ectopically expressed in tachyzoites and localized by 
immuno-fluorescence. TgEK with the C-terminal HA-tag (TgEK-HA) under control of the 
pNTP3 promoter displayed a uniform cytosolic pattern, which co-localized with a bona fide 




Fig. 6: TgEK is uniformly cytosolic in T. gondii. TgEK harboring the C-terminal HA-tag (TgEK-HA) 
was expressed under the control of the pNTP3 promoter, and co-localized with the parasite actin 
(TgAct). The HFF infected with transfected tachyzoites were immuno-stained 29 hrs post-infection 
using the mouse anti-TgActin (TgAct, red, 1:1000) and rabbit anti-HA (green, 1:1000) antibodies. Bar, 
5 µm. 
 
Interestingly, TgCK possesses an N-terminal hydrophobic sequence, which is predicted to act 
as a signal peptide in the database. Our attempts to localize TgCK with the N- or C-terminal 
HA-tag in stable transgenic parasites using a strong promoter such as pNTP3 were 
unproductive. Hence, we designed a construct expressing TgCK under the control of its native 
regulatory elements and harboring the C-terminal HA-tag (TgCK-HA), which allowed us to 
assess its localization. Unexpectedly, TgCK-HA demonstrated a punctate intracellular 
staining, which did not co-localize with the known dense granule or cytosolic proteins such as 
TgGra1, TgGra3 or TgActin. (Fig. 7A) To exclude a localization artifact due to interference 
with the C-terminal epitope, we performed the N-terminal-tagging of TgCK, which rendered 
the protein undetectable suggesting that the N-terminus is required for localization. The 
atypical subcellular distribution and the possible requirement of the N-terminus for optimal 
targeting prompted us to express TgCK fused with a Ty1 epitope after the N-terminal 
hydrophobic peptide (HP). TgCK-Ty1 also showed a similar dotted intracellular presence, 




Fig. 7: TgCK displays a punctate intracellular distribution. (A) TgCK does not co-localize with 
dense granule (TgGra1, TgGra3) or cytosolic (TgAct) marker proteins. (B) TgCK isoforms with the C-
terminal HA-tag (TgCK-HA) or a Ty1-epitope (TgCK-Ty1) following the hydrophobic peptide (HP) 
were co-expressed under the control of the native regulatory elements. The parasititized HFF were 
immuno-stained 29 hrs post-infection using anti-HA (from mouse or rabbit, 1:1000), the mouse anti-
TgCK serum (1:200), mouse anti-TgActin (1:1000), mouse anti-TgGra1 (1:500), mouse anti-Ty1 
(1:50), and rabbit anti-TgGra3 (1:500) antibodies. Bar, 5 µm. 
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To further substantiate these findings, we generated the mouse antiserum against the purified 
and truncated TgCK (see below). An N-terminally 6xHis-tagged TgCKS (6xHis-TgCKS) 
lacking its hydrophobic N-terminal sequence (first 20 amino acids), was subjected to 
thrombin protease treatment to remove the 6xHis epitope and subsequently injected into 
BALB/c mice (with alum as adjuvant) 3 times at 2 weeks intervals. The antiserum specifically 
identified a 70-kDa band corresponding to choline kinase in the protein extract prepared from 
parasitized human fibroblasts and free parasites but not from uninfected cells (Fig. 8).  
 
Fig. 8: Anti-TgCK-serum specifically identifies a 70-kDa choline kinase in T. gondii lysate. 
Western blot of uninfected or infected HFFs or the axenic tachyzoite using the mouse TgCK antiserum 
(1:200). 30 µg of the protein extract was resolved by 12% SDS-PAGE and blotted to identify the 
parasite choline kinase using anti-TgCK serum (1:200) and HRP-conjugated secondary antibodies 
(1:3000). 
 
Yet again, we observed a punctate intracellular pattern in wild-type parasites when stained 
with anti-TgCK serum (Fig. 9A), which remained unchanged in extracellular parasites (Fig. 
9B). Immuno-staining of the transgenic parasites expressing TgCK-HA with TgCK antiserum 
and anti-HA antibody revealed a perfect co-localization (Fig. 9C). Taken together, our results 
demonstrate that TgCK has a distinct punctate intracellular distribution, whereas TgEK is 
uniformly cytosolic in T. gondii tachyzoites.  
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Fig. 9: Anti-TgCK serum confirms a punctuate intracellular localization. The intracellular (A) and 
extracellular (B) hxgprt
-
 parasites were immuno-stained using anti-TgCK serum (green, 1:200) and 
anti-TgGap45 (red, 1:3000). Intracellular parasites were fixed 29 hrs post-infection. (C) TgCK-HA 
was expressed under its native relulatory elements in the T. gondii hxgprt
-
 strain and stained with 
mouse anti-TgCK serum (green, 1:200) and rabbit anti-HA antibody (red, 1:1000) 29 hrs post-
infection. Bar, 5 µm. 
 
3.3 TgCCT is nuclear, whereas TgCPT resides in the ER 
Next, we expressed the C-terminally HA-tagged TgCCT (TgCCT-HA) under pTetO7Sag1 
promoter, which localized to the parasite nucleus as determined by its co-staining with DAPI 
(Fig. 10A).  
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Fig. 10: TgCCT localizes to the nucleus in intracellular and extracellular tachyzoites. The C-
terminally HA-tagged TgCCT (TgCCT-HA)  was expressed under the pTetO7Sag1 promoter and 
NTP3-3’UTR and localized in intracellular and extracellular parasites by IFA (A) or IEM (B) using 
mouse anti-HA antibody (green, 1:1000; co-localization with rabbit anti-TgGap45, red, 1:3000; and 
DAPI, blue). For IEM the anti-HA (1:200) and the protein A-gold (10 nm)-conjugated secondary 
antibody were used. N, nucleus.  
 
CCT catalyzes the rate-limiting reaction of PtdCho synthesis and the activity of mammalian 
CCT is regulated by its reversible binding to the nuclear membrane (59). External triggers, 
such as depletion of cellular PtdCho, can cause the translocation and activation of the soluble 
and nuclear CCT into a membrane-bound form. Surprisingly, TgCCT showed a persistent 
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localization in the parasite nucleoplasm in intracellular as well as extracellular tachyzoites 
with no indication of redistribution to the nuclear membrane (Fig. 10A). This was further 
supported by immuno-gold electron microscopy (IEM) using the rat anti-HA and protein A-
gold (10 nm)-labeled antibodies, which confirmed a nucleuar expression of TgCCT-HA (Fig. 
10B).  
TgCPT-HA, on the other hand, was confined to the ER as shown by immuno-fluorescence 
assays (Fig. 11). The co-localization studies with TgCPT could not be performed due to 
unavailability of an antibody against a bona fide ER protein. The results, however, are 
consistent with the expression of mammalian CPT in the ER (27). 
 
Fig. 11: TgCPT-HA localizes to the endoplasmic reticulum of T. gondii tachyzoites. The TgCPT-
HA was expressed under the pTetO7Sag1 promoter and NTP3-3’UTR, and IFA of parasitized HFF was 
performed using  the mouse anti-HA (green, 1:1000) and rabbit anti-TgGap45 (red, 1:3000) antibodies 
29 hrs post infection. Bar, 5 µm. 
 
3.4 The N-terminal peptide is required for oligomerization of TgCK 
To identify the organelle underlying the punctate intracellular presence of TgCK, we 
performed IEM using the anti-TgCK serum. Notably, this revealed the formation of enzyme 
clusters in the parasite cytosol, and no association with any organelle and/or membrane was 
detectable in the wild-type RH strain (Fig. 12A). Further, IEM of the transgenic hxgprt
-
 
parasites stably expressing TgCK-HA revealed a perfect co-localization of both, the native 
and ectopic forms of choline kinases, when labeled with the rat anti-HA and mouse anti-TgCK 
serum as primary antibodies and protein A/gold (anti-rat, 5 nm; anti-mouse, 10 nm)-
conjugated secondary antibodies (Fig. 12B) 
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Fig. 12: TgCK forms clusters in the T. gondii cytosol. (A) Immuno-gold electron microscopy of 
wild-type parasites using TgCK antiserum (primary, 1:250) and protein A/gold (10 nm)-conjugated 
(secondary) antibodies. (B) The transgenic hxgprt
-
 parasite line stably expressing TgCK-HA was 
labeled with the rat anti-HA (1:200) and mouse anti-TgCK serum as primary antibodies (1:250) and 
protein A/gold (anti-rat, 5 nm; anti-mouse, 10 nm)-conjugated secondary antibodies to co-localize the 
native and ectopic isoforms of TgCK. Mn, microneme; DG, dense granule; Rh, rhoptry; PV, 
parasitophorous vacuole; N, nucleus.  
 
Further assays determined the role of the N-terminal hydrophobic peptide in formation of the 
enzyme clusters. To this end, we transfected hxgprt
-
 tachyzoites with the C-terminally myc-
tagged and truncated TgCK lacking its first 20 residues (TgCKS-myc), and localized the 
protein with anti-myc antibody and anti-TgCK serum. TgCKS-myc exhibited a more uniform 
distribution in the parasite cytosol confirming that the N-terminus of TgCK is indeed required 
for its punctate distribution (Fig. 13). The TgCKS-myc expression was lost in most parasites 
during the transgenic selection, which indicated an apparent toxicity of the truncated TgCK. 
Interestingly, we observed a redistribution of the full-length native as well as of ectopic HA-
tagged TgCK isoforms from clusters into a more uniform cytosolic pattern (Fig. 13) indicating 
that the hydrophobic peptide serves as an anchor to support the formation of enzyme clusters. 
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Fig. 13: The TgCK hydophobic N-terminus is required for enzyme clustering. TgCK lacking its N-
terminal hydrophobic peptide (first 20 aa) and containing a myc-tag at the C-terminus (TgCKs-myc, 
red) was regulated by the pGRA2 in hxgprt
-
 tachyzoites. IFA was performed using mouse anti-TgCK 
serum (1:200), mouse anti-HA (1:1000) and rabbit anti-myc (1:1000) antibodies 29 hrs post-infection.  
 
3.5 TgCK and TgEK encode active choline and ethanolamine kinases 
To classify the TgCK and TgEK proteins as choline and/or ethanolamine kinases according to 
their substrate specificity, we examined their activity by radioactive enzyme assay. TgCK and 
TgEK with the C-terminal 6xHis epitope were expressed and purified from E. coli Rosetta 
strain. TgEK-6xHis could be purified to apparent homogeneity as deduced by a 60-kDa 
protein on SDS-PAGE (Fig. 14). The purified TgCK-6xHis, however, contained two smaller 
species in addition to the expected 70-kDa band; these two smaller species were confirmed as 
alternative or degradation products of the TgCK-6xHis ORF by western blot using the mouse 




Fig. 14: Purified recombinant TgCK-6xHis and TgEK-6xHis. The full-length ORF of TgCK and 




 vector were expressed in E. coli 
Rosetta strain. The purity and identity of TgCK was tested by coomassie-stained 12% SDS-PAGE 
(left) and western blot (right) using mouse anti-TgCK serum (1:200) or mouse anti-6xHis antibody. 
 





and the reaction products were analyzed by thin layer chromatography (TLC). The choline 
and ethanolamine kinases of S. cerevisiae (ScCK1, YLR133W; ScEK1, YDR147W) were 
cloned into the galactose-inducible pESC-Ura vector and expressed in the ∆ck1/∆ek1 yeast 
mutant (KS106), which was used as a positive control. The yeast extract of the mutant 
transfected with the empty pESC-Ura served as a negative control. The recombinant TgCK 
phosphorylated choline as a major and ethanolamine as its second substrate, as determined by 
co-migration of products with the corresponding controls (Fig. 15).  By contrast, TgEK 
displayed a kinase activity only for ethanolamine confirming its function as a substrate-
specific kinase.  
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Fig. 15: TgCK phosphorylates choline and ethanolamine, whereas TgEK is specific to 
ethanolamine. Thin layer chromatography of resolved catalytic products of choline and ethanolamine 
kinases. The products (P-Cho, P-Etn) were identified by their co-migration with respective controls. 
Purified TgCK-6xHis or TgEK-6xHis was incubated with [
3
H]-choline (Cho) or with [
3
H]-
ethanolamine (Etn) (37°C, 10 min) prior to TLC analysis (95%EtOH/2%NH4OH, 1:1). The products 
were detected by phospho-imaging for 72 hrs at RT. Cell free extracts (CFE) from the S. cerevisiae 
KS106 (∆ck1/∆ek1) expressing ScCK1 or ScEK1 or harboring the empty vector (pESC-Ura) served as 
the positive and negative controls.  
 
To determine the enzyme kinetics of TgCK with choline, the assay was performed with 
increasing substrate concentrations (2.5 nCi/nmol, 0-3.2 mM), and reaction products were 
quantified by liquid scintillation counting. TgCK-6xHis displayed a typical Michaelis-Menten 
kinetics with a relatively high Km value of 0.77 mM (Fig. 16). Together, the data indicate that 
TgCK is a low-affinity enzyme, which can phosphorylate choline and ethanolamine, whereas 




Fig. 16: Michaelis-Menten kinetics of purified TgCK-6xHis protein by radioactive choline kinase 
assay. Activity was determined by scintillation counting of phosphocholine from [
3
H]-choline chloride 
(2.5 nCi/nmol, 0–3.2 mM, 4 min, 37°C). For the assay details refer to section 2.4.4. 
 
3.6 The N-terminal hydrophobic peptide is not required for function of TgCK 
To examine whether the hydrophobic peptide is important for TgCK catalysis, we expressed a 
truncated protein lacking the first 20 amino acids with the N-terminal 6xHis-tag (6xHis-
TgCKS) in E. coli Rosetta strain and purified the enzyme to apparent homogeneity (Fig. 17B). 
Next, we established a 96-well-plate spectrophotometric assay for a user-friendly evaluation 
of the enzyme kinetics. The ATP-dependent catalysis by choline kinase initiates a cascade of 
three enzymatic reactions, the last of which involves the oxidation of NADH. Hence, 
monitoring a decline in the NADH absorbance (340 nm) allows an indirect monitoring of the 
choline phosphorylation (54). The full-length TgCK-6xHis displayed a relatively low affinity 
for choline (Km = 0.74 mM) (Fig. 17A), which is in accordance with the data obtained from 
radioactive assay. Quite noticeably, the 6xHis-TgCKS displayed ~3-fold higher affinity for 
choline (Km= 0.26 mM) when compared to full-length TgCK-6xHis, which indicated a 
potential conformational change in 6xHis-TgCKs (Fig. 17B), besides the fact that the N-
terminal sequence is not necessary for TgCK catalysis. 
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Fig. 17: The N-terminal hydrophobic peptide is not required for catalysis by TgCK. Michaelis-
Menten kinetics of TgCK-6xHis (A) and 6xHis-TgCKs (B) with choline using a pyruvate 
kinase/lactate dehydrogenase-coupled assay. Activity was monitored by decrease in the NADH 
absorbance (340 nm). For the assay details refer to section 2.4.4.  
 
3.7 TgCK is inhibited by a choline analog, dimethylethanolamine (DME) 
The earlier work has shown that DME can block in vitro growth of T. gondii in HFF cells 
(38). Lipid analyses of the drug-treated parasites showed a time-dependent accrual of a 
PtdCho analog (PtdDME) and equivalent and concurrent (38) reduction in PtdCho, indicating 
that the anti-parasite effect of DME is due to interference with the PtdCho metabolism. TgCK 
initiates the PtdCho biogenesis in T. gondii; therefore, it is also a likely enzyme being 
inhibited by DME. Hence, we first reconfirmed the anti-parasite effect of DME in plaque and 
replication assays. There was no plaque formation in the presence of 2 mM DME (Fig. 18A), 
and the drug treatment caused inhibition of the parasite replication as judged by formation of 
smaller vacuoles. About 80-100% of vacuoles harbored only 2-4 parasites. In contrast, the 
untreated sample contained 4-8 tachyzoites in ∼80% of vacuoles (Fig. 18B).  
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Fig. 18: Intracellular replication of T. gondii is inhibited by a choline analog, 
dimethylethanolamine (DME). (A) Confluent monolayers of human foreskin fibroblasts were 
infected with 200 parasites, and plaques were stained with crystal violet after 7 days of infection. (B) 
The number of parasites per vacuole was counted by anti-TgGap45 IFA (1:3000) 29 hrs post-infection 
with or without 2 mM DME treatment. In total, 3 independent assays, each with 50 vacuoles were 
evaluated.  
 
We next determined the enzyme kinetics of TgCK for choline and DME using the radioactive 
and photometric assays. Interestingly, TgCK-6xHis phosphorylated DME with an apparent Km 
value of 0.94 mM, which is similar to the Km for its natural substrate choline (Fig. 19A). In 
accordance, DME inhibited phosphocholine formation by TgCK-6xHis in radioactive assays 
exhibiting a Ki of 0.84 mM and IC50 of 0.95 mM (Fig. 19B). Likewise, the truncated 6xHis-
TgCKS showed similar affinities for the analog (Km, 0.25 mM) and for choline (Fig. 19C).  
To evaluate the mechanism of DME inhibition, we compared the TgCK-6xHis kinetics in the 
absence or presence of saturating amount of DME (2 mM). The radioactive assay revealed 
that the presence of DME increased the Km of TgCK for choline by about 3-fold without 
influencing the Vmax, suggesting a competitive inhibition of TgCK by the analog (Fig. 19D).  
The kinetic parameters of DME metabolism by TgCK are consistent with the observed 
reduction of PtdCho synthesis and with the inhibition of parasite cultures by DME (IC50 ∼0.5 
mM) (38). These data suggest that the reported anti-parasite effect of DME is likely due to 




Fig. 19: A choline analog DME can competitively inhibit the activity of the purified choline 
kinase. (A) Michaelis-Menten kinetics of TgCK-6xHis with DME was monitored by decrease in the 
NADH absorbance (340 nm) in a pyruvate kinase and lactate dehydrogenase-coupled assay. (B) Effect 




H]-choline (0.1 mM, 0.25 
nCi/nmol) by purified TgCK-6xHis was measured for 4 min at 37°C. (C) Michaelis-Menten kinetics of 
6xHis-TgCKS with DME (C) was monitored by decrease in the NADH absorbance (340 nm) in a 
coupled-enzyme assay. Values are means ±S.E. for three experiments. (D) Competitive inhibition of 




3.8 Displacement of pTgCK by a conditional promoter 
The susceptibility of parasite cultures and of endogenous PtdCho synthesis to an inhibitor of 
TgCK implied an essential role of this enzyme for the parasite, which required verification by 
manipulation of the gene. Our attempts to directly delete the TgCK locus in hxgprt
-
 and ∆ku80 
tachyzoites were futile. The recombination-specific PCR identified only single crossover 
events at the 5’- or 3’-end except for one clone, which had undergone double homologous 
recombination (Fig. 20A, B). Surprisingly, however, the PCR and sequencing revealed that 
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this putative knockout parasite still expressed TgCK transcript (Fig. 20C). Similar results 
showing only 5’- or 3’-recombination events were obtained when using the crossover-
efficient (∆ku80) strain of T. gondii.  
 
Fig. 20: The direct knockout of the TgCK gene via double homologous crossover. (A) Scheme of 
the TgCK deletion in the ∆ku80 or hxgprt- strain of T. gondii. The 3.3-kb of the 5’- and 3’-UTRs of 
TgCK were cloned into the p2854-DHFR-TS vector flanking the DHFR-TS resistance cassette. (B) 
The recombination-specific PCR using TgCK-KO-5’Scr-F/DHFR-R2 and DHFR-F2/TgCK-KO-3’Scr-
R primers, respectively, revealed 5’- and 3’-crossover in a putative ∆tgck mutant. (C) The mRNA was 
isolated from wild-type and the putative ∆tgck parasites, which revealed presence of TgCK transcript 
in the wild-type (WT) as well as in the putative ∆tgck strain (Primer Table 1).  
 
We, therefore, pursued conditional ablation of the TgCK expression by means of the promoter 
displacement approach. In this regard, we made an inducible parasite line (∆tgcki) via 
displacing the pTgCK promoter by the pTetO7Sag4 in the TaTi-∆ku80 strain, which allows an 
efficient homologous recombination and tetracycline-regulatable expression. The promoter-
displacement (PD) construct harbored the 5’UTR (2 kb) preceding the start codon and the 
partial TgCK gene fragment (1 kb), both inserts flanking the DHFR-TS (selection marker) and 
the pTetO7Sag4 promoter (Fig. 21A). The pyrimethamine-resistant transgenic parasites were 
selected, cloned, and analyzed for displacement of the pTgCK. The construct-specific PCR of 
positive clones revealed the DHFR-TS cassette adjacent to the 5’- and 3’-UTRs in the genome 
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of the ∆tgcki mutant and in the construct (control) but not in the parental gDNA (Fig. 21B). 
Likewise, PCRs for the 5’- and 3’-crossovers amplified the expected DNA bands in the 
promoter-displaced (∆tgcki) parasites but not in the parental gDNA and control construct. 
Sequencing of the 5’- and 3’-bands confirmed the events of homologous crossover exactly at 
the TgCK gene locus in the ∆tgcki strain. 
 
Fig. 21: Conditional mutatgenesis of the TgCK gene via promoter displacement method. (A) 
Scheme of the pTgCK displacement by a tetracycline-regulatable pTetO7Sag4 promoter in the TaTi-
∆ku80 strain of T. gondii. The 2-kb of the promoter region and 1-kb following the initiating codon 
(ATG) of TgCK were cloned flanking the pTetO7Sag4 and DHFR-TS resistance cassette in the 
pDT7S4 vector. (B) Construct-specific PCR (TgCK-PD-5’UTR-F/DHFR-R and DHFR-F/TgCK-PD-
3’UTR-R) confirmed expected bands in the plasmid and in the ∆tgcki gDNA, but not in the parental 
strain. The recombination PCR using TgCK-PD-5’Scr-F/DHFR-R and DHFR-F/TgCK-PD-3’Scr-R 
primers amplified 5’- and 3’-crossover products in the ∆tgcki mutant but none with control construct or 
parental gDNA. The 5’- and 3’-PCR bands were confined by sequencing. For primers see Table 1. 
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3.9 PtdCho biogenesis can occur despite a major knockdown of full-length 
TgCK in T. gondii 
The IFA and western blot using the anti-TgCK serum confirmed the anhydro-tetracycline 
(ATc)-mediated regulation of TgCK in the promoter-displaced ∆tgcki strain. The ∆tgcki 
expressed a reduced level of choline kinase when compared to the parental strain indicating a 
depletion of the full-length TgCK protein in the transgenic strain upon promoter displacement 
(Fig. 22A). The punctuate staining became undetectable following 48-hrs culture in ATc (Fig. 
22A). Surprisingly, despite a reduction (control) or an apparent complete loss (ATc-treated) of 
TgCK expression, the ∆tgcki mutant exhibited no discerneable growth defect by plaque assay, 
which was confirmed by quantitative scoring of the plaque sizes (Fig. 22B). The transgenic 
strain also survived continued passage in cultures irrespective of the presence of ATc. 
Consistently, the replication assays also showed no difference in the vacuole size between the 
mutant and parental strain (Fig. 22C). 
Next, we compared the major phospholipid profile of the mutant with the parental strain. Total 
lipids of the extracellular parasites were separated by TLC and visualized by iodine-staining.  
No apparent change in the iodine staining of PtdCho and other major phospholipids (PtdEtn 
and PtdSer) of the ∆tgcki strain was observed in untreated cultures, and a reduction of about 
30% was observed in the PtdCho content after ATc treatment (Fig. 22D). The individual 
phospholipids were also quantified by chemical phosphorous assay, which confirmed a 
similar (~30%) drop in PtdCho content (Fig. 22E).  
These results demonstrate that despite a major knockdown of ~70-kDa TgCK, T. gondii can 
ensure its survival and produce PtdCho for membrane biogenesis and ensure its survival. 
Moreover, a normal parasite growth despite a reduced PtdCho content in the off state indicates 
a compositional plasticity of the parasite membranes and the inability of parasite to scavenge 





Fig. 22: Knockdown of TgCK does not affect the parasite growth and PtdCho biogenesis. (A) 
TgCK expression under the native promoter in the TaTi-∆ku80 strain or under the control of the 
conditional promoter (pTetO7Sag4) in the ∆tgcki strain in the presence or absence of ATc (0.5 µM). 
Intracellular tachyzoites were stained 29 hrs post-infection using rabbit anti-TgGap45 antibody (red, 
1:3000, inner membrane complex marker) and mouse anti-TgCK serum (green, 1:200). Bar, 5 µm. (B) 
The representative plaques formed by the ∆tgcki and the parental strain incubated with or without Atc 
(0.5 µM). Confluent monolayers of human foreskin fibroblasts were infected with 200 parasites, and 
plaques were stained with crystal violet 7 days post-infection. The size quantification was performed 
by ImageJ suite. (C) Replication of the ∆tgcki strain with or without ATc (0.5 µM) was determined by 
IFA (anti-TgGap45, 1:3000) 29 hrs post-infection and counting of the parasites per vacuole. 50 
vacuoles were counted each in 3 independent experiments. (D) Iodine staining of TLC-resolved 
phospholipids from the ∆tgcki and parental strains. Lipids from equivalent numbers of parasites were 
extracted, separated by TLC (CHCl3/CH3OH/H2O, 65:25:4), and then visualized by iodine vapors. The 
ATc (0.5 µM) treatment was performed for several passages in culture. (E) Phosphorous quantification 
of the ∆tgcki lipid. Axenic tachyzoites of the TaTi-∆ku80 strain and the ∆tgcki mutant in the on (-ATc) 
or off (+ATc) state were washed once with PBS and counted. Total phospholipids were extracted and 
resolved by TLC (CHCl3/CH3OH/H2O, 65:25:4). Lipids were scraped off from the iodine-staned plate 
and quantified for their phosphorous content as desribed in section 2.4.7.  
 
3.10  Choline kinase activity cannot be abolished in the ∆tgcki mutant 
Our further work focused on elucidating the mechanism underlying survival and membrane 
biogenesis in the ∆tgcki mutant. We tested the TgCK protein expression in the conditional 
mutant by western blot analysis. Surprisingly, in addition to the full-length ~70-kDa TgCK, 
we observed the expression of a smaller protein (~53-kDa) recognized by anti-TgCK serum in 
the ∆tgcki mutant (Fig. 23A). The expression of this protein coincided with the disappearance 
of full-length TgCK in the untreated sample and persisted despite the ATc treatment for 48 
hrs. The high intensity images of the ∆tgcki corroborated these findings, and identified a 
punctate cytosolic plus ATc-regulatable fluorescence representing the full-length TgCK (Fig. 
23B). The images also revealed a fluorescence in the mitochondrion and/or endoplasmic 




Fig. 23: The ∆tgcki mutant expresses a novel protein, recognized by anti-TgCK serum. (A) 
Western blot of the extract from the ∆tgcki and TaTi-∆ku80 strains using the mouse anti-TgCK serum 
(1:200). The parasite actin, identified by mouse anti-TgAct (1:1000) served as a loading control. (B) 
High intensity fluorescent imaging of the ∆tgcki mutant 29 hrs post-infection using rabbit anti-
TgGap45 antibody (red, 1:3000) and mouse anti-TgCK serum (green, 1:200). Bar, 5 µm. 
 
We next examined the choline kinase activity in the total parasite extract of the ∆tgcki mutant. 
The radioactive choline kinase assay was performed for 30 min and products were analyzed 
by scintillation counting (Fig. 24A) and TLC (Fig. 24B). In consistence with the western blot 
and immuno-fluorescence, the enzyme assay revealed synthesis of phosphocholine by the 
mutant extract, indicating the presence of a functional choline kinase. Only ~33% of the total 
kinase activity was regulatable with ATc (Fig. 24A). We next tested the ∆tgcki mutant for its 
ability to metabolize choline into PtdCho during replication by labeling the intracellular 
parasite with [
14
C]-choline and evaluating for the synthesis of radioactive lipids (Fig. 24C, D). 
Yet again ~35% decrease in the total lipid counts was observed in ATc-treated cultures (Fig. 
24C, D). The persistence of choline kinase activity, and choline labeling of the parasite 
PtdCho confirm the presence of an active choline kinase in the ∆tgcki strain.  
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Fig. 24: TgCK activity and PtdCho synthesis cannot be abolished in tgcki mutant. (A) Choline 
kinase activity was measured in the protein extract (25 µg) using [
14
C]-choline (0.1 µCi, 10 µM, 30 
min, 37°C) and phosphocholine formation was quantified or visualized by TLC (95% 
EtOH/2%NH4OH, 1:1) and (B) X-ray exposure of the TLC plate at -80°C for 1 month. (C) The 
parasitized (MOI=3) monolayers of human foreskin fibroblasts were cultured for 40 hrs in media 
containing [
14
C]-choline (0.1 µCi/ml). Parasites were washed twice with PBS, and lipids were 
extracted for TLC analysis (CHCl3/CH3OH/H2O, 65:25:4). (C) [
14
C]-Choline labeling into 
phospholipids was visualized by exposure of the TLC plate to X-ray film for 48 hrs (D) Quantification 
of lipid labeling by scintillation counting. The ATc (0.5 µM) treatment was performed for several 
passages in culture.   
 
In accord, similar to the parental strain the ∆tgcki mutant was susceptible to competitive 
inhibition of choline kinase activity by DME, which impaired the replication in both strains 
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(Fig. 25). The untreated control cultures displayed 4-8 tachyzoites in ∼80% of vacuoles, and 
∼15-20% of them harbored 2 parasites. A prominent decrease in the number of parasites per 
vacuole was observed in DME-treated samples, where vacuoles showed only 2-4 tachyzoites.  
 
Fig. 25: The ∆tgcki mutant is susceptible to inhibition by DME. Parasites in their vacuoles were 
counted in the parasitized HFF (29 hrs post-infection) following staining with rabbit anti-TgGap45 
antibody (1:3000). Values are means ±S.E. for 3 independent experiments, each with 50 
parasitophorous vacuoles.   
 
3.11 The exon1 of the TgCK gene harbors a potential promoter 
Next, we attempted to identify the source of choline kinase activity in the mutant. A weak 
expression of the 53-kDa protein detected by anti-TgCK serum hampered its identification by 
mass spectrometry. The Toxoplasma genome harbors 2 additional choline/ethanolamine 
kinases, one of which (TgEK) was confirmed as an ethanolamine-specific kinase in this work. 
This protein should not contribute to the observed choline kinase activity in the ∆tgcki. 
Besides, our attempts to amplify the third putative choline/ethanolamine kinase 
(TGGT1_058210) using the mRNA isolated from wild-type tachyzoites or from the ∆tgcki 
mutant were not successful. The RNA sequencing and proteomic data (www.ToxoDB.org) 
also show no evidence for expression of this gene in T. gondii tachyzoites. 
 Alternatively, the observed activity could be due to use of an alternative (secondary) 
promoter and/or an alternative start codon in the TgCK gene. To test this, we performed 
quantitative PCR of the ∆tgcki mRNA following treatment with Atc (Fig. 26). Three different 
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primer pairs were used, two of which annealed in the first exon and the third amplified a 
fragment of the exon 6 (Appendix 6). Interestingly, the EST corresponding to Exon1-2 primer 
pair (binding in the first half of exon1) was less abundant and appeared at cycle 25. The other 
two ESTs (Exon1-1 binding in the second half of exon1, and primer pair annealing in exon6) 
were more abundant and visible at cycle 22. These data indicated the presence of at least two 
type of transcripts comprising of two in-frame start codons present in the exon1 (1-1893 bp 
and 493 -1893 bp). These transcripts would code for proteins of 630 amino acids (~70-kDa) 
and 466 amino acids (~53-kDa), the latter corresponding to the smaller protein observed in 
the ∆tgcki mutant. Different levels of transcript also imply the presence of an alternative 
promoter. All three ESTs responded to regulation with ATc. However, a modestly stronger 
downregulation by ATc was observed with the primers annealing in the first half of the exon1 
(primer Exon1-2 in Fig. 26). Collectively, these data indicate the presence of a weakly active 
alternative promoter within the first exon, which is not regulatable by Atc, and produces a 
shorter transcript translating into a functional choline kinase of ~53-kDa.  
 
Fig. 26: Expression analysis of TgCK transcript by real-time PCR. The total RNA was isolated 
from the ∆tgcki mutant in the absence or presence of ATc (0.5 µM, 148 hrs) and the parental strain 
cultures. 100 ng of total RNA were transcribed into the first-strand cDNA using Oligo(dT) and random 
hexamer primers at Ta of 60°C. qPCR was performed using primers annealing in exon-1 or -6 of TgCK 
and the transcript abundance was calculated as ∆ct by subtracting the ct from the housekeeping 
transcripts (TGGT1_124740, TgGT1; TGGT1_037840, TgElf1a).  
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3.12  The Knockdown of a putative TgCCT causes a growth defect in T. gondii 
The conditional mutagenesis of TgCK could not convincingly adress the essentiality of CDP-
choline pathway. Therefore, a conditional knockout of the rate-limiting enzyme, TgCCT, was 
generated in the TaTi-∆ku80 strain to further test the essentiality of de novo PtdCho synthesis. 
The C-terminally HA-tagged TgCCT ORF (TgCCTi-HA) under the control of the pTetO7Sag1 
promoter and NTP3-3’UTR was cloned into plasmid pTetUPKO. The expression cassette was 
flanked by 800 bp of the 5’- and 3’-UTRs of the TgUPRT (uracil phosphoribosyl transferase) 
gene for the insertion of TgCCTi-HA at the locus by double crossover (Fig. 27A). Disruption 
of the UPRT locus renders the parasite insensitive to FUDR (5-fluorodeoxyuridine), which 
otherwise blocks the parasite replication by interfering with the DNA synthesis (18). Stable 
transgenic parasites were selected for 3-4 weeks using 5 µM FUDR and the expression plus 
tetracycline-regulation of TgCCTi-HA was verified by IFA. The TgCCTi-HA strain was then 
transfected with the TgCCT knockout construct. To this end, the 1 kb of 5’- and 3’-UTRs of 
the TgCCT gene were cloned into p2854-DHFR-TS flanking the resistance cassette, which 
allowed selection of stable parasites with 1 µM pyrimethamine (Fig. 27A). The clonal 
parasites obtained by dilution plating were analyzed for the double crossover events at the 
TgCCT locus by PCR. As described above for the ∆tgcki mutant, recombination-specific 
PCRs for the 5’- and 3’-ends amplified the expected DNA bands in the knockout parasites 
(∆tgcct/TgCCTi-HA) but not in the parental gDNA and in control construct (Fig. 27B). The 
homologous integration event was confirmed by sequencing of both PCR products. The 
absence of endogenous TgCCT locus was verified further by PCR using the ORF-specific 
primers (Fig. 27C), which yields a 2 kb fragment corresponding to the size of the genomic 
TgCCT locus in wild-type parasite gDNA. The parental strain which, besides the endogenous 
gene, also expressed TgCCTi-HA, displayed a second PCR fragment of 1 kb. Whereas, as 
expected, the ∆tgcct/TgCCTi-HA mutant lacked the larger 2 kb fragment corresponding to the 
gene locus, and showed expression of only the 1 kb cDNA, which validated the deletion of 




Fig. 27: Conditional mutagenesis of the TgCCT locus. (A) Schematic depiction of a regulatable 
TgCCT knockout generated in two steps. TgCCT-HA under the control of the pTetO7Sag1 promoter 
(TgCCTi-HA) was cloned into pTetUPKO plasmid, which allows the selection of transgenic parasites 
with FUDR for stable integration at the TgUPRT locus. In the next step, the 1kb of 5’- and 3’-UTRs of 
TgCCT were introduced into p2854-DHFR-TS flanking the resistance cassette, and the NotI-linearized 
construct was transfected into the TaTi-∆ku80 strain of T. gondii expressing the TgCCTi-HA. Stable 
parasites were selected with 1 µM pyrimethamine and cloned by limiting dilution. (B) Construct-
specific PCR using TgCCT-KO-5’UTR-F/DHFR-R and DHFR-F/TgCCT-KO-3’UTR-R confirmed 
expected bands in the plasmid and in the ∆tgcct/TgCCTi-HA gDNA, but not in the parental strain. The 
recombination PCR using TgCCT-KO-5’Scr-F/DHFR-R and DHFR-F/TgCCT-KO-3’Scr-R primers, 
revealed 5’- and 3’-crossovers in the ∆tgcct/TgCCTi-HA mutant but none with control construct or the 
parental gDNA. (C) TgCCT ORF-specific primers revealed expression of the 1kb cDNA and 2kb 
genomic locus in the TaTi-∆ku80 strain expressing the regulatable TgCCTi-HA (parental). PCR on 
hxgprt
-
 parasites results in 2kb amplicon, whereas the genomic locus is absent in the ∆tgcct/TgCCTi-
HA mutant, which expresses only the 1kb cDNA.  
 
Next, we examined the knockdown of TgCCTi-HA expression following treatment with ATc 
(Fig. 28A, B). Two protein bands of 40- and 37-kDa, of which the lower band corresponds to 
the predicted size of TgCCT protein, were observed. Both isoforms were substantially 
downregulated following 24 hrs treatment, and disappeared completely after 72 hrs of 
treatment (Fig. 28A).  This was confirmed by IFA, where the protein was detectable in the 




Fig. 28: Regulation of TgCCT expression in the ∆tgcct/TgCCTi-HA mutant. (A) Western blot of 
total parasite extract prepared following Atc (1 µM) treatment as indicated. The rabbit anti-HA 
antibody (1:1000) revealed depletion of TgCCTi-HA in the ∆tgcct/TgCCTi-HA mutant after ATc 
treatment. Actin served as the loading control. (B) IFA of the ∆tgcct/TgCCTi-HA mutant cultured 
without or with ATc (1 µM) for 29 or 110 hrs post-infection (mouse anti-HA, green, 1:1000; rabbit 
anti-TgGap45, red, 1:3000; DAPI, blue). Bar, 5 µm. 
 
The Atc treatment of the ∆tgcct/TgCCTi-HA mutant caused a marked growth defect as 
deduced by plaque and replication assays. The plaque size of the ∆tgcct/TgCCTi-HA was 
similar to the parental strain in the absence of ATc, whereas in the off state the plaque size in 
the mutant was reduced to about 50% (Fig. 29A, B). This was mirrored by the formation of 
smaller vacuoles in replication assays, where about 70% of the parental vacuoles harbored 8-
16 parasites per vacuole. Whereas ~56% of the mutant vacuoles contained 2-4 parasites in 
contrast to ~30% in the parental strain (Fig. 29C).  
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Fig. 29: The knockdown of TgCCT reduces the parasite replication. (A) The representative plaques 
formed by the ∆tgcct/TgCCTi-HA and the parental strain. Confluent monolayers of HFFs infected with 
200 parasites were cultured without or with 1 µM ATc, and plaques were stained with crystal violet 7 
days post-infection. (B) Quantification of plaque size of ∆tgcct/TgCCTi-HA and the parental strain 
using the ImageJ suite. (C) Intracellular replication of the ∆tgcct/TgCCTi-HA mutant was measured by 
counting the number of parasites per vacuole 29 hrs post infection. The parasites were stained using 












4.1 CDP-choline and CDP-ethanolamine pathways of T. gondii 
Similar to other eukaryotes, PtdCho and PtdEtn are the two most abundant phospholipids in 
the membranes of Toxoplasma gondii (38). The T. gondii genome (www.ToxoDB.org) harbors 
the predictions for the CDP-choline and the CDP-ethanolamine pathway, which are the major 
routes of PtdCho and PtdEtn biogenesis in mammalian cells (Fig. 30). Similarly, the parasite 
is competent in utilizing choline and ethanolamine into PtdCho and PtdEtn, respectively (38), 
but, however, lacks a PtdEtn methyltransferase to make PtdCho from PtdEtn (Fig. 30).  
The three enzymes of the CDP-choline pathway in T. gondii – TgCK, TgCCT and TgCPT – 
display a differential localization in the cytosol, nucleus and ER membrane, respectively (Fig. 
30). The first reaction is catalyzed by TgCK, which besides its major substrate choline can 
also phosphorylate ethanolamine. An anti-parasite choline analog DME can competitively 
inhibit TgCK (Fig. 30). A truncated enzyme, lacking the N-terminal hydrophobic peptide, 
shows about 3-fold increased activity towards choline and DME. The TgCCT showed best 
homology to the mammalian CCT-alpha isoform, and localizes to the parasite nucleus. 
However, unlike mammalian CCTs, which regulate their activity by a reversible attachment to 
the nuclear membrane (59), the TgCCT showed a persistent nuclear staining in the 
intracellular and extracellular tachyzoite. This implies a different mechanism regulating the 
TgCCT activity, which probably does not require the protein re-localization. TgCPT localizes 
to the ER membrane as also known for its orthologs (27). The differential subcellular 
distribution of TgCK, TgCCT and TgCPT raises the obvious question of how their catalytic 




Fig. 30: De novo synthesis of phospholipids in T. gondii.  The H. sapiens and P. falciparum pathways 
are adapted from literature, and of T. gondii are constructed based on the reported enzyme activities 
and annotations in the parasite database (www.ToxoDB.org). The pathways, common to all organisms, 
are shown in black; and those specific to human, are depicted in green. The SDPM-pathway, shown in 
purple, denotes a plant-type route for PtdEtn and PtdCho synthesis, and is exclusive to P. falciparum. 
Initial precursors are shown in blue; the intermediates of lipid synthesis are in black; phospholipids are 
in red, and the enzymes are depicted in brown color. DME is metabolized via the CDP-choline route 
and produces PtdDME, which is not methylated to PtdCho in T. gondii causing disruption of 
membrane biogenesis. The treatment of parasite cultures with DME leads to a reduction in PtdCho and 
an accumulation of PtdDME. CK, choline kinase; PCT, phosphocholine cytidylyltransferase; CPT, 
CDP-choline phosphotransferase; EK, ethanolamine kinase; PET, phosphoethanolamine 
cytidylyltransferase; EPT, CDP-ethanolamine phosphotransferase; PEMT, phosphatidylethanolamine 
methyltransferase; PMT, phosphoethanolamine methyltransferase; SD, serine decarboxylase; PSS, 
phosphatidylserine synthase; PSD, phosphatidylserine decarboxylase; DME, dimethylethanolamine. 
 
Our futile attempts to generate a TgCK knockout parasite line by direct deletion suggest that 
choline kinase activity is required for PtdCho biogenesis, and thereby also for the parasite 
survival. Despite an apparent knockdown of the full-length TgCK in a conditional mutant, 
choline kinase activity could not be abolished in the on and off states. The choline kinase 
activity in the mutant was reduced only by ~33%, which translated into ~27% reduction in the 
PtdCho content of tachyzoites. Surprisingly, despite a reduction in total PtdCho, the parasite 
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growth was not influenced. T. gondii appears not to be capable of salvaging PtdCho or its 
intermediates from the host cell, which would otherwise alleviate the reduction in PtdCho 
content. This implies a strict dependence of T. gondii on its CDP-choline pathway (i.e. choline 
auxotrophy). Moreover, these results suggest that the reported anti-parasite effect of DME is 
likely not a consequence of decline in PtdCho content but an effect of accumulated PtdDME, 
which due to absence of a PtdEtn methyltransferase in T. gondii is not further methylated to 
form PtdCho and eventually causes a disruption of the membrane integrity and inhibits the 
parasite replication (Fig. 30). Toxoplasma also lacks a serine-decarboxylase 
phosphoethanolamine methyltransferase pathway (SDPM), a second plant-type route of 
PtdCho synthesis in P. falciparum. Disruption of the PtdCho synthesis by chemical inhibition 
of PfCK or by the genetic deletion of PfPMT are detrimental to the P. falciparum growth 
(40,60). Despite an apparent redundancy of PtdCho biogenesis, disruption of either pathway 
strongly reduces the growth of the malaria parasite suggesting their role in formation of 
different pools of PtdCho. In contrast, this work indicates that the related parasite Toxoplasma 
depends on de novo CDP-choline pathway for PtdCho biogenesis.  
 
4.2 Novel features of TgCK and its therapeutic exploitation 
The use of anti-parasite choline analogs is an effective approach to block growth of a variety 
of parasites including T. gondii (38,60,61). Quite notably, the Km of full-length choline kinase 
encoded by TgCK (0.77 mM) for choline is many-fold higher than parasite (PfCK, 0.14 mM, 
(60); TbCK, 0.032 mM, (61)) and non-parasite (HsCKα1, 0.2 mM, (62); ScCK, 0.27 mM, 
(63)) peers. In addition, TgCK protein harbors a novel hydrophobic sequence at the N-
terminus that is nonessential for catalysis but appears to be required for its clustering in the 
cytosol. The deletion of the N-terminal peptide presumably changes the conformation of 
TgCK and increases the protein affinity by 3-fold (0.26 mM), which is in range of other 
choline kinases. Formation of choline kinase oligomers has been reported in S. cerevisiae 
(63). Moreover, the three isoforms of mouse choline kinase (α1, α2, β) can form in vitro 
homo-/hetero-oligomers, which have been attributed to enzyme regulation (64). The closely 
related parasite P. falciparum with a monomeric cytosolic choline kinase, however, appears to 
represent an exception (65). Whether the clustered form of TgCK in the cytosol is more 
efficient in phosphorylating choline, or if the enzyme clusters can compensates for low 
affinity by sequestered catalysis of substrate should be investigated. Irrespective of the 
mechanism, disruption of PtdCho synthesis by competitive inhibition of CDP-choline 
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pathway is an effective strategy to disrupt the membrane biogenesis and replication of T. 
gondii.  
 
4.3 Plasticity of PtdCho biogenesis in T. gondii 
The ability to tolerate a perturbation of the PtdCho biogenesis varies between organisms. The 
mutation of CCT and reduction in PtdCho content has been reported to be lethal in CHO cells. 
A temperature-sensitive mutant of CHO cells could only be rescued by exogenous PtdCho. 
Interestingly, PtdEtn methyltransferase cannot circumvent the disruption of the CDP-choline 
pathway in CHO cells (66,67). Conversely, PtdCho and N-methylated lipids in S. cerevisiae 
are considered as non-essential on non-fermentable carbon sources (68). The results presented 
here suggest that the PtdCho biogenesis in T. gondii likely occurs via the CDP-choline route. 
Similar to yeast, however, the decline in PtdCho is tolerated by Toxoplasma without affecting 
its replication and viability.  
Toxoplasma appears to harbor different mechanisms to circumvent or compensate for the loss 
of individual enzyme activities to ensure biogenesis of PtdCho. Interestingly, displacement of 
the TgCK promoter by a conditional promoter coincides with the detection of a 53-kDa non-
regulatable protein in/on mitochondrion or endoplasmic reticulum of the ∆tgcki mutant. 
Assuming that there is no other choline kinase expressed in tachyzoites, our data would 
suggest a shorter isoform of full-length TgCK being responsible for the residual activity in the 
∆tgcki mutant. Our qPCR data imply the presence of a promoter within the exon1, which 
produces a shorter and non-regulatable transcript. There are two in-frame start codons (amino 
acid position 165 and 244), which may lead to the synthesis of of 53-kDa and 45-kDa 
proteins, respectively (Appendix 6). The detection of the shorter isoforms in the parental 
strain may have been hampered by the higher abundance of the full-length TgCK (~70-kDa). 
Affinity purification of the TgCK antibody from the here-reported antiserum might increase 
the specificity and may allow the detection of the isoform(s) with lower abundance. The short 
isoform(s) arising from the second promoter and/or alternative start codon contain the 
predicted choline kinase and Brenner’s motifs, and therefore should encode funtional 
enzymes. Testing this notion would require expression of a reporter protein (e.g. GFP) under 
the control of the first exon and expression cloning of shorter variants of TgCK.  
The conditional mutagenesis of putative TgCCT caused a slower replication, which resulted in 
formation of 50% smaller plaques as compared to the parental strain. The enzymatic activity 
of TgCCT towards phosphocholine, however, remains to be proven that is necessary to 
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correlate the observed growth defect to a disruption of PtdCho synthesis in the mutant. The 
assumption that TgCCT is involved in PtdCho synthesis suggests yet another mechanism in T. 
gondii to compensate for its depletion as discussed below. The Toxoplasma genome also 
encodes for a putative ECT (TGGT1_008370). Whether T. gondii ECT and CCT have 
overlapping activity could not be extablished during this work. Moreover, transcriptomic 
studies have shown an upregulation of human CCT in parasitized cells (69), which may 
provide CDP-choline for PtdCho biogenesis in T. gondii.  
Finally, sphingomyelin can be degraded by sphingomyelinases to yield phosphocholine. The 
presence of a putative sphingomyelinase (TGGT1_081220) in Toxoplasma provides a second 
source of phosphocholine in T. gondii, which could dispense the function of TgCK (Fig. 31). 
These pathways together can provide an unexpected flexibility of PtdCho biogenesis to the 





Fig. 31: Current model of the PtdCho biogenesis in T. gondii. The scavenging of NBD-PtdCho 
(micellar or LDL-conjugated) likely does not contribute to the PtdCho biogenesis in T. gondii, whereas 
NBD-PtdEtn and NBD-PtdSer are salvaged, which may involve lipid transfer from the host ER and 
mitochondria juxtaposed to the PVM. The parasite appears to be a choline auxotroph, utilizing choline 
into PtdCho via the de novo CDP-choline pathway. Activity of TgCK can potentially be made 
dispensable by a sphingomyelinase (SMase), which cleaves sphingomyelin (SM) into ceramide (Cer) 
and phosphocholine (P-Cho). Host CCT (HsCCT) is upregulated in parasitized HFFs and might 
provide CDP-choline to the replicating parasite. TgCK, TgCCT and TgCPT localize in the parasite 
cytosol, nucleus and ER, respectively. Therefore, synthesis of PtdCho in the ER would require 
trafficking of its intermediates (P-Cho, CDP-Cho) from the cytosol to nucleus and ER. LDL, low-
densitiy lipoprotein; PV, parasitophorous vacuole; PVM, PV membrane 
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4.4 Potential redundancy of PtdEtn biogenesis and enzyme activities in T. 
gondii 
The ability of Toxoplasma to utilize ethanolamine into PtdEtn suggests the presence of a 
functional CDP-ethanolamine pathway, which should involve the activity of TgEK, TgECT 
and TgEPT enzymes (38). Although not proven in this work, the CDP-ethanolamine pathway 
appears to be a major route of PtdEtn synthesis in Toxoplasma. PtdEtn can also be derived via 
decarboxylation of PtdSer by a PtdSer decarboxylase (PSD). Similar to Saccharomyces 
cerevisiae, the Toxoplasma genome harbors predictions for two types of PSDs 
(TGGT1_108460, TGGT1_080780). Whereas the yeast PSD1 and PSD2 localize in the 
mitochondria and Golgi membrane, respectively, and produce compartment-specific lipid 
pools (70), more experiments are  required to characterize the TgPSD proteins in detail. 
Plasmodium and Trypanosoma species possess a dual-specificity choline kinase and a 
substrate-specific ethanolamine kinase (60,61), whereas in S. cerevisiae both enzymes have 
interchangeable function (71,63). In this respect, the TgCK is akin to its parasite peers. It is 
possible that TgCK can compensate for the loss of TgEK activity, and thereby support PtdEtn 
synthesis in the parasite. T. gondii, therefore, harbors a variety of potentially redundant 
pathways to synthesize and/or salvage its second most abundant phospholipid, PtdEtn.  
Interchangeable activities have also been reported for CPT and EPT. Human, S. cerevisiae and 
Plasmodium are known to harbor choline- and/or ethanolamine-phosphotransferases, which 
are capable of utilizing CDP-choline and/or CDP-ethanolamine as the phosphobase donors 
(72,73,74). The substrate specificity is probably regulated by the availability of certain co-




. In addition, S. cerevisiae also possess a CPT protein restricted 
to CDP-choline (71). It remains to be seen wether TgCPT and TgEPT have redundant 
catalytic activity. To this end, we attempted the functional expression of TgCK, TgCCT, 
TgCPT (and TgEPT) in various expression models, namely E. coli and S. cerevisiae mutants 
to assess their specific enzymatic activities. Our attempts to express the C-terminally 6xHis-
tagged isoforms in E. coli were not fruitful. No protein expression was detectable in the 
coomassie-stained gel or by western blot upon induction with IPTG (Appendix 5A). We also 
performed the heterologous expression in S. cerevisiae mutants, which were also not 
successful in confirming the enzyme activity (Appendix 5B).  
All proteins were also over-expressed as their C-terminally V5-tagged isoforms under the 
pCMV promoter in COS-7 cells. The transgenic expression confirmed the aforementioned 
localization of TgCK, TgCCT and TgCPT/TgEPT to the cytosol, nucleus and ER, respectively 
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(Fig. 32). None of the transgenic extracts expressing TgCCT, TgCPT/EPT yielded CDP-
choline formation with radioactive phosphocholine in the CCT assay (Appendix 5C). Due to 
the unavailability of the head-group (choline) labeled CDP-choline, we were unable to assess 
TgCPT/TgEPT activity. Finally, we over-expressed the C-terminally HA-tagged TgCCT 
(TgCCT-HA) under the pNTP3 promoter in T. gondii and tested the parasite extract for CCT 
activity. Yet again, no activity was observed in the transgenic or control samples (Appendix 
5D).  
Taken together, the functional expression of the TgCCT/TgECT and TgCPT/TgEPT remains 
unsolved and requires future assay optimization.  
 
Fig. 32: Heterologous expression of TgCK, TgCCT, TgCPT (and TgEPT, Accession number 
TGGT1_008370) in COS-7 cells. The cDNAs of TgCK, TgCCT, TgCPT and TgEPT with the C-
terminal V5-epitope were cloned at XbaI/HindIII sites into plasmid pcDNA3.1
+
 under the control of 
the pCMV promoter. The BglII-linearized constructs were transfected into COS-7 cells using the 
lipofectamine method (section 2.4.9).  IFA was performed 24 hrs post-infection using the rabbit anti-
V5 antibody (green, 1:1000; co-stained with Phalloidin-Alexa595 (1:40) labeling the cellular F-Actin, 




4.5 Contribution of lipid scavenging to membrane biogenesis in T. gondii 
The axenic parasite can synthesize sufficient amount of PtdEtn required for one cell doubling, 
whereas the rates of PtdSer and PtdCho synthesis are sufficient only for 50% and 9% of the 
parasite lipid requirement, respectively (38). This discrepancy between the demand and 
supply of PtdCho and PtdSer is possibly resolved by an increased rate of synthesis and/or 
scavenging of lipids by the intracellular tachyzoites. The PVM-recruitment of host 
endoplasmic reticulum and mitochondria offers potential sources of host cell lipids to the 
parasite. The majority of choline-containing lipids, such as PtdCho and sphingomyelin, reside 
in the exoplasmic membrane leaflet of eukaryotic membranes (34), therefore, the inward-
directed movement and import of PtdCho is probably not favored. The CHO cells have been 
shown to bypass a suppression of their CDP-choline pathway by uptake of PtdCho or lyso-
PtdCho from the media (66). S. cerevisiae can also internalize exogenous PtdCho and PtdEtn 
(75). Whereas PtdEtn is internalized solely via transbilayer transport, the translocation of 
PtdCho involves endocytosis, as opposed to the former mechanism (76,77). The parasite 
genome harbors predictions for P4-type ATPases, specific transport proteins involved in 
phospholipid translocation across membranes in yeast and mammalian cells (35). Whether 
Toxoplasma is capable of endocytosis, which may be necessary for the transport of lipids from 
the PVM lumen to the parasite interior, remains to be investigated (78). Our data (Marquardt 
S, unpublished data) using the tracer lipids in their micellar form exclude the prospect of 
PtdCho scavenging by T. gondii. Wheras PtdSer and PtdEtn were trafficked across the parasite 
membranes, PtdCho was largely excluded by the parasites (Fig. 31). The recruitment of low-
density protein (LDL) by T. gondii can supply cholesterol to the parasite (79), which makes 
then use of the Host Organelle-Sequestering Tubulo-structures (H.O.S.T.). Being rich in 
PtdCho (80), LDL also offers a route to obtain this lipid. The labeling of intracellular parasites 
with NBD-conjugated lipids (PtdCho, PtdEtn or PtdSer) loaded onto human LDL-particles 
yielded only a weak NBD signal in the parasite membranes and/or vacuolar space with all 
three samples (Fig. 33), but no staining was apparent within the parasite body. These 
preliminary data indicate that LDL-derived phospholipids likely provide only a minor 





Fig. 33: Scavenging of host LDL-derived phospholipids by intracellular T. gondii tachyzoites. The 
C6-NBD-phospholipids were conjugated to human LDL-particles (37°C overnight) prior to LDL 
isolation by zonal density gradient ultracentrifugation. Confluent HFF monolayers grown on glass 
coverslips in the lipoprotein-deficient serum were infected (MOI = 3), and 28 hrs post infection NBD-
loaded LDL particles (0.1 mg/ml) were added. Samples were fixed following 1 hr incubation at 37°C, 




This work suggests T. gondii as being a choline auxotroph, which utilizes choline into PtdCho 
via the de novo CDP-choline pathway (Fig. 31). The parasite shows an unexpected robustness 
to the genetic perturbation of the TgCK and TgCCT, which indicates alternative routes of 
PtdCho biogenesis in T. gondii as highlighted in Figure 33. The low affinity of choline kinase 
offers a potential target for therapeutic application and our plate-based spectrometric assay 
offers a cost-effective platform to screen for TgCK inhibitors. 
Future experiments should include the functional characterization of CDP-choline 
phosphotransferase (TgCPT) and deletion of TgCCT to confirm the essentiality of the CDP-
choline pathway. The substrate specificities of TgCCT/TgECT and TgCPT/TgEPT should also 
be assessed for and unambiguous interpretation of the observed phenotypes in the two 
mutants. Insertional tagging of the TgCK gene with a destabilization domain offers an 
alternative technique to confirm the essential nature of choline kinase.  
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Transcriptomic studies can reveal potential pathways used by the parasite mutants to 
circumvent the mutagenesis of TgCK and TgCCT. The reported data on the contribution of 
host-derived lipids via rerouting of LDL-pathway require validation with internal control such 
as the LDL-NBD-cholesterol. Potential host candidates, which may provide the intermediates 
of PtdCho or the lipid itself, should also be investigated. This requires detailed studies genetic 







Appendix 1: The TgCK cDNA encodes a choline kinase with 630 residues, which shows 19%, 
16% and 10% identity with HsCKα, PfCK and ScCK1, respectively. The best homologies are 
found in the Brenner’s (red box) and choline kinase (blue box) motives. TgCK also harbors an N-
terminal hydrophobic peptide (first 20 amino acids; magenta box) with no homology to a known 
protein in the NCBI database. The NCBI accession numbers are: HsCKα, NP_001268.2; PfCK, 
PF14_0020; ScCK1, YLR133W. 
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Appendix 2: The TgEK cDNA encodes an ethanolamine kinase with 547 residues, which shows 
21%, 20% and 14% identity with HsEK1α, PfEK and ScEK1, respectively. The NCBI accession 





Appendix 3: The TgCCT cDNA encodes a protein of 329 amino acids with 30% and 26% 
homology to HsCCT-alpha and ScCCT, respectively. TgCCT possesses a putative nuclear 
localization signal (NLS) between the residues 154 and 166 (red box). Accession numbers: HsCCT-













Appendix 4: The TgCPT cDNA encodes a protein with 467 residues. TgCPT shows 20%, 26% and 
19% homology to HsCPT, PfEPT and ScCPT respectively. The catalytic domain 
DG(X)2AR(X)8G(X)3D(X)3D is highlighted in the red box. Accession numbers: HsCPT, 









Appendix 5: Expression of TgCCT, TgCPT and TgEPT in transgenic models. (A) The ORF of 
TgCCT (38-kDa), TgCPT (52-kDa) and TgEPT (49-kDa) were cloned as their C-terminally 6xHis-
tagged isoforms into plasmid pET41b+ (NdeI/NotI). Expression in the E. coli Rosetta strain was 
induced with 1 mM IPTG overnight at 30°C. The total protein extract (10 µg) was separated on 12% 
SDS-PAGE and stained with coomassie blue or subjected to western blot using the anti-6xHis 
antibody (1:10000). The empty plasmid pET41b+ served as the negative control. (B) The TgCCT ORF 
was cloned in pESC-His (NotI/NotI) under the galactose-inducibe promoter pGAL10 and expressed in 
S. cerevisiae mutants Y04832 (∆cct1) or Y04637 (∆ect1). The ScCCT and ScECT served as the 
positive controls. Yeast extract of transfected Y04832 and Y04637 was generated using 0.45 – 0.6 mm 
glass beads, and 100 µg of total extract was supplemented with 100 µl reaction buffer (final 
concentration 58 mM Tris (pH 7.5), 40 mM NaCl, 1.8 mM EDTA, 8.9 mM magnesium acetate), 3 mM 
CTP and 0.1 µCi [
14
C]-phosphocholine (P-Cho). The assay was performed for 5 min at 30°C (ScCCT, 
ScECT) or at 37°C (TgCCT). The reaction was stopped by 2 min heating, and the formation of 
radiolabeled CDP-choline (CDP-Cho) was analyzed by TLC (95% EtOH/2%NH4OH, 1:1). X-ray film 
was exposed overnight at -80°C. (C) The TgCCT, TgCPT and TgEPT were expressed with the C-
terminal V5-tag under the pCMV promoter in plasmid pcDNA3.1
+
. All constructs and the empty 
plasmid were linearized with BglII, transfected into COS-7 cells using the lipofectamine method 
(section 2.4.9) and stable cells were achieved by selection with geneticin. 100 µg of total protein 
extract was prepared and tested for TgCCT activity for 30 min at 37°C. (D) TgCCT-HA was expressed 
under the pNTP promoter in hxgprt
-
 parasites and stable parasites were obtained by selection with 1 
µM pyrimethamine. 100µg of total parasite extract was assayed for TgCCT activity for 30 min at 37°C 




Appendix 6: Sequence of the gDNA depicting TgCK cDNA. TgCK-Ex1-F2/R2 primers (grey) bind 
in the first half of exon1; TgCK-Ex1-F1/R1 primers (brown) anneal in the second half of exon1; 
TgCK-Ex6-F1/R1 primers (green) anneal in exon6. These primer pairs were used to amplify the 
corresponding ETSs by qPCR on the ∆tgcki mutant and parental strain. The start codon coding for the 
full-length TgCK (70-kDa), and the possible shorter isoforms (53-kDa and 45-kDa) are depicted  in 
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